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ABSTRACT 
Ornithine decarboxylase (ODC) is the primary and rate-limiting enzyme in the natural 
synthesis of polyamines putrescine, spermidine and spermine, which have been 
implicated in the breakdown of the blood-brain barrier (BBB), the initial event in the 
pathogenesis of experimental allergic encephalomyelitis (EAE) and multiple sclerosis 
(MS). This thesis INOUid like to suggest that there is increased expression of ODC during 
heightened disease expression in EAE, and therefore that ODC is involved in the 
development of EAE and MS through the polyamine synthetic pathway. 
To assess the levels of ODC enzyme in central nervous system (CNS) tissue, which 
included cerebellum, cervical spinal cord and medulla, the tissue was first homogenised 
and the protein concentration of the resulting sample determined. This required the 
establishment of an appropriate protein estimation mP.thod i.e. a suitable protein assay. 
Much time and experimentation was spent on achieving this because of the effect of 
interfering substances on the assays used. 
Assessment of the levels of ODC in a model of EAE using normal tissue, CFA treated 
tissue (control), day-13 post inoculation (PI) (height of disease) and day-21 PI (early 
recovery stage) was carried out by Western blotting. The studies show that there is 
increased expression of ODC at the height of disease i.e. day-13 PI in cerebellum and 
medulla pons tissue but not cervical spinal cord tissue. 
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1.0. INTRODUCTION 
1.1. Autoimmune Disease 
Autoimmune diseases arise when the body's immune system attacks its own cells and/or 
tissue having identified the cell(s) and/or tissue as an antigen. Autoimmune diseases 
include myasthenia gravis in which muscle tissue is attacked, periarteritis nodusa in 
which arterial walls become inflamed, systemic lupus erythamatisis in which there is 
superficial inflammation of the skin with scaling patches, rheumatoid arthritis in which 
cartilage and synovial membrane become enlarged through inflammation, and multiple 
sclerosis (MS) in which there is inflammation of CNS tissue and demyelination. 
The common clinical characteristics of autoimmune diseases include higher incidence in 
the female gender, a relapsing course, and precipitation uf disease activity by viral 
infections. Autoimmune diseases also have genetic linkage through immune response 
genes in the major histocompatibility (MHC) complex region of chromosome six. The 
mechanism by which the autoimmune response is initiated is not clearly understood, 
however various theories have been put forth and are discussed later on in this thesis. 
1.2. Multiple Sclerosis 
MS is a chronic disease of autoimmune origin that begins in late adolescence or early 
adulthood and has both highly variable expression and severity (Lynch, Rose, 1996). MS 
is best described as an inflammatory disease of the central nervous system (CNS) white 
matter characterized by focal T cell and macrophage infiltrates leading to demyelination, 
axonal injury and loss of neurological function (Bar-Or eta/. 1999). In the earliest stages 
of MS the myelin sheaths at the patches/plaques, where focal inflammation occurs, break 
up and are absorbed leaving the nerve fibres bare thus forming the sclerosis or patch. 
Connective tissue comprised of neuroglia is later formed between the fibres, further 
hindering proper nerve function. 
Symptoms of MS, among others, include; muscle weakness and plasticity; impairment of 
pain; inability to differentiate temperatures; abnormal touch sensation with pain ranging 
from moderate to severe; ataxia, tremor, speech and vision disturbances; vertigo; 
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bladder, bowel, and sexual dysfunction; depression; euphoria, and cognitive 
abnormalities. In the worst cases MS can render a person unable to write, speak, or walk, 
and may result in death. 
MS may be manifested as a relapsing-remitting (RR) condition, in which case the disease 
is characterized by a series of attacks that result in varying degrees of disability from 
which the patient recovers partly or completely, usually followed by a remission period of 
variable duration before another attack. Alternatively in the primary-progressive (PP) form 
of the disease there is lack of acute attacks and instead there is a gradual clinical decline 
(Bar-Or, eta/. 1999). The PP form of the disease shows a more rapid rate of deterioration 
than the RR form of the disease (Cottrell eta/. 1999). About two thirds of MS patients 
have the RR course (Poser and Brinar, 2001 ). 
1.2.1. Incidence and Prevalence of MS 
Although MS is found in many geographical regions it is often in clusters. The main areas 
of occurrence are areas inhabited by peoples of Northern European descent (Oger, Lai , 
1994; Hader, Elliot, Ebers, 1988; Poser, Brinar, 2000) such as North America, Europe 
(especially western Europe), the United Kingdom (Chataway, 1989) and N. Ireland 
(McDonnell, Hawkins, 1998), and Australia (Hammond, eta/. 2000) suggesting a genetic 
basis to the disease and also implicating commonality in lifestyle i.e. similar diet, socio-
economic, and maybe even cultural factors. This is consistent with the observation that 
Caucasians are more than twice as likely as other races to develop MS (Poser and 
Brinar, 2001; Giovannoni, 1997; Hogancamp, et a/. 1997). MS is the major cause of 
neurological disability in the Western Hemisphere (Bar-Or, eta/, 1999). 
MS typically manifests between the ages of 20 and 40 and rarely has onset after the age 
of 60 years. Onset of MS in juveniles younger than 15 years old is rare and disease 
progression in juveniles is not dependent on age of onset; nor does it determine severity 
of neurological involvement, or polysymptomatic or monosymptomatic involvement at 
presentation (Pinhas-Hamiel eta/, 1998). 
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In general, women are affected at almost twice the rate of men (Granieri, et at., 1996; 
McDonnell, Hawkins, 1998) however, among patients who develop the symptoms of MS 
at a later age (~ 40), the gender ratio is more balanced. The high prevalence of MS in 
women led to the study of MS in association with pregnancy and the hormonal cycle of 
women. It has been shown that the rate of relapse of MS declines during pregnancy, 
especially in the third trimester, and increases during the first three months after delivery 
before returning to the pre-pregnancy rate (Confavreux et at, 1998). Endogenous steroids 
may play a part in the remission of symptoms during pregnancy due to their 
immunosuppressive effect. This is an observation consistent with the effect of pregnancy 
on other autoimmune diseases (Abramsky, 1994). Although a protective effect of 
estrogens on the development and progression of MS has also been suggested by 
experimental and clinical data, use of oral contraceptives, i.e. synthetic steroids, has not 
been associated with significant reduced risk of MS (Hernan et at, 2000; Abramsky, 
1994). As the aetiology of MS is yet unknown, the treatment and prevention of MS is 
directed at the treatment of the associated symptoms. Synthetic steroids have been used 
in the treatment of the inflammation reaction in MS probably working in much the same 
manner as natural immunosuppressive substances (Abramsky, 1994) released by the 
body during pregnancy such as human placental lactogen, human choroinic 
gonadotropin, early pregnancy factor, pregnancy-associated plasma protein A, and a-
Fetoprotein. 
1.2.2. Suggested Causes of MS 
Although the specific cause{s) of MS is unknown, epidemiological studies support both 
genetic and non-genetic factors supporting the theory that non~netic influences work on 
pre-existing genetic factors to cause MS (Kurland, 1994; Poser, 1993; Calder et at, 1989; 
Lynch, 1996). The environmental or non-genetic component is supported firstly, by the 
presence of clusters or small epidemics of MS, secondly geographic variation in 
prevalence and thirdly by the fact that changes in susceptibility to the development of MS 
can be altered by migration, i.e. increasing risk with migration from an area of low 
prevalence to one of high prevalence. That MS has a genetic basis is supported by the 
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increased risk for development of MS in relatives of MS patients. Further support is 
provided by the presence of MS-resistant ethnic groups e.g. in some groups Africans 
especially in sub-Sahara Africa that have low incidence levels (Hogancamp eta/, 1997). 
1.2.2.1 Genetic Causes of MS 
Relatives of patients with MS have been shown to have a higher incidence or greater 
susceptibility to autoimmune diseases and at the same time, studies into autoimmune 
disease have shown a general diathesis in patients with MS (Broadley et at, 2000). For 
example a sibling of an MS patient is 15 times more likely to develop MS than the rest of 
the population (Chataway, 1989), and the risk of developing MS among first-degree 
relatives of patients with MS is increased 15-20 times ov~ the risk of the general 
population (Chataway, 1989; Tournier-Lasserve and Bach, 1993). 
The higher incidence rate for MS in monozygotic whe:n compared with di-zygotic twins 
also supports genetically influenced susceptibility (Calder eta/, 1989). In distant relations, 
the chance of developing MS is higher than chance expectation in the general population, 
but lower than that expected for closely related individuals. Multiple interacting genes 
seem to play a role in this increased risk of MS (Dessa et a/, 2001 ). 
Genetic susceptibility in a person will determine if that person will develop the MS "trair 
(Poser, 1993). The MS trait is defined as, "a permanent state of hyperactive or intensified 
immunocompetent responsiveness or capability, which is triggered in the genetically 
susceptible individual by exposure to a non-specific antigen that is almost certainly of 
viral origin, either an acute viral infection or a vaccination." (Poser, 1993). The MS trait 
thus makes a person a potential victim of MS. 
The events that trigger the genes of a susceptible include infectious agents, bacteria or 
viruses, may possess proteins that induce an autoimmune response due, to possession 
of proteins that share similar epitopes to host (self) proteins, i.e. they mimic self. This 
molecular mimicry theory proposes that infectious agents contain proteins with peptide 
sequences that mimic autoantigen peptides, which upon presentation in the periphery 
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inadvertently activate autoreactive T -cells (Bar-Or, eta/, 1999) that may find their way into 
the CNS. 
Alternatively, association between MS and thyroid disorders, in particular hypothyroidism, 
also lends support to the autoimmune pathogenesis of MS. The principle function of the 
thyroid is the control of growth and the rate of metabolism achieved though production 
and secretion of thyroxin hormone, which controls the metabolism of all cells and tissues. 
1' Thyroid disorders are at least three times as common in women with MS than in female 
I' controls (Kami and Abramsky, 1999). The high rate in of hypothyroidism disease in 
women supports the proposition of a genetic component to MS susceptibility as genetic 
diseases seem to be preponderate in women i.e. genetic diseases are more prevalent in 
the female gender and thyroid disorders are more common in women with MS than 
controls suggesting a possible genetic predisposition to MS. 
I 
Another genetic component to MS may involve the major histocompatibility complex 
(MHC) also known as the human leukocyte antigen (HLA) region. The MHC/HLA region is 
a set of closely linked genes situated on the short arm of chromosome 6, that are 
involved in the presentation of antigens to the immune system in general and T cells in 
particular. HLA class II genes, i.e. HLA-DR, DQ and DP with separate sub-regions for 
each of the DR, DQ and DP, are important in the regulation of the immune response 
against peptide antigens by coding for polymorphic proteins expressed on the surface of 
most nucleated cells. The HLA class II molecules detennine whether the individual will 
react immunologically to a given antigen thus making HLA class II molecules tt e most 
important immune response genes. 
Strong associations between HLA and susceptibility to autoimmune disease have been 
described. Conversely, certain HLA antigens occur together more frequently than would 
be expected by chance, and may have a protective effect, conferring resistance to a 
disease. Barcellos eta/ (1997) discuss gene loci on the HLA as a potential factor 
conferring susceptibility toMS however only the haplotype DR15/DQ6 has a confirmed 
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role in MS (Hillert, 1994). The observation that MS patients have similar gene sequence 
in the HLA region in particular the DR 15/006 haplotype, supports the proposition that 
genes are an important factor in the autoimmune aetiology of MS although the 
mechanism by which the DR15/DQ6 haplotype contributes to the ability to develop MS is 
not clear. 
1.2.2.2 Non-Genetic Causes 
Non-genetic factors have are also important in the aetiology of MS (Casetta and Granieri , 
2000; Giovanni, 1997). These include geographical region especially as related to 
latitude, exposure to solar light, and socio-economic status or level of development i.e. 
the hygiene hypothesis (Rook and Brunet, 2002). 
MS is fiVe times more prevalent in temperate climates, such as those found in the 
northern United States, Canada, and Europe, than in tropical regions. There is also an 
indication that an individual migrating between areas of variable risk before the age of 15 
tends to adopt the risk of the new area (Chataway, 1989; Kurland, 1994; Giovannoni, 
1997). In the United States where much work has been done in relation to geographical 
distribution of MS, a higher incidence of MS has been found in northern areas compared 
with the south, an observation consistent with the north/south divide disease profile in 
other countries and regions (Hernan eta/, 1999). Considering that the large majority of 
this population in this region is of similar genetic make up i.e. largely Caucasian, the 
difference in the occurrence of MS is more correctly attributed to non-genetic factors. 
Over the last few decades, a more balanced occurrence of MS in the southern areas of 
Europe as compared to the northern areas has led to questioning whether latitude is 
indeed a factor affecting the development of MS. 
The observation that people of the same geographical region share the same diet in 
general, are exposed to similar conditions such as sunlight intensity (influencing vitamin 
D production) and agents of infection, rather than just the fact that the people are by and 
large of the same race with similar genes, is probably a large factor in the aetiology of 
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MS. That is, the increased incidence associated with a certain area may be due to 
environmental rather than genetic factors. 
Although there is currently insufficient evidence for a single or unique non-genetic cause 
of MS, various agents have been suggested. Of these viruses have received the most 
attention (Marrie et at, 2000; Giovannoni, 1997; Kurtand, 1994; Johnson, 1994). Other 
suggested factors include allergies arising from exposure to animals and plants, toxins, 
trauma, and diet rN'fnn, et a/1989). 
One explanation given for the role of viruses in the initiation of MS is that common viruses 
such as measles share epitopes with MS autoantigens (Giovannoni, 1997). The 
proposition that viruses may be a cause of MS is supported by the three main findings 
(Johnson, 1994) as follows. Firstly, epidemiological studies indicate that exposure in 
childhood to certain viral agents precedes exacerbation. Secondly, studies in animal 
models and patients of autoimmune diseases have shown that viruses can cause 
diseases with long incubation periods, remitting and relapsing courses and myelin 
destruction mediated by variety of mechanism. Thirdly, patients with MS have been 
shown to have abnormal immune responses to virus infection such as measles, influenza 
C and Herpes simplex viruses (HSV). 
No specific virus to which the onset of MS can be attributed has been definitively shown 
(Cermelli and Jacobson, 2000). Some of the viruses that have been studied include the 
HSV types 1 and 2 for which the age at which HSV-2 is first detected and the age at peak 
incidence are similar to those forMS (Martin, 1981 ); Ixodes genus tick viruses to which 
high rates of MS have been linked, especially with the distribution of certain island human 
populations relate to the distribution of Ixodes genus tick viruses (Brown, 1996). Ixodes 
ticks and their associated viruses are globally distributed by polar-migrating seabirds, 
which are important food sources for some island and coastal communities that also have 
a high rate of MS. However, this increased incidence may instead be due to the 
European ancestry of the island population. 
An association between a history of infectious mononucleosis (IM) and MS has was 
shown by case-control study in which ina-eased frequency of respiratory tract infections 
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(RTI) was associated with a significantly increased risk of MS (Marie et a/, 2000), thus 
supporting the proposition that a history of IM may precipitate disease onset. 
In contrast, adults with a history of childhood optic neuritis seem to have a lower risk of 
recurrence and progression of MS compared to adults who do not have a history of optic 
neuritis (Lucchinetti eta/, 1997) possibly suggesting a suppressive or preventative effect 
on the presentation of MS. 
Environmental conditions, however adverse they may be, cannot on their own be 
considered triggering factors for the initiation of MS. It is likely that a multiplicity of 
environmental conditions working together on a genetic framework, i.e. "MS traif', lead to 
the initiation of MS disease. The genetic factors that make an individual susceptible to 
MS are varied and the mechanisms involved in disease aetiology have not been 
uncovered. In addition, the importance of ethnic homogeneity of patients and control 
subjects cannot be overemphasized in prevalence and risk factor considerations. Both 
nature, genetic, and nurture, non-genetic factors play important interdependent roles in 
the aetiology of MS. 
1.2.3. Immunology of MS 
Whatever the cause or initiation of the inflammatory response in MS, activation and 
proliferation of leukocytes will occur. In the case of MS, the inflammation lasts over a long 
period of time i.e. leads to the development of state of chronic inflammation. 
Activated macrophages and T lymphocytes are the predominant cell types in the CNS of 
MS patients (Hatler and Weiner, 1989; Calder eta/, 1989; Fretland, 1992; Paul eta/, 
2000). Macrophages are of central importance in MS pathology because they are 
antigen-presenting cells (APC), produce both myelinotoxic and neurotoxic factors, and 
are also capable of phagocytosis and remyelination (Giovannoni, 1997). They also 
produce cytokines, chemokines and tumour necrosis factor alpha (TNF-a), which drive 
the inflammatory response. 
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In particular MS is suggested to be a T cell mediated disease of the CD4+ T cell subtype 
(Prat and Martin, 2002; Hatler and Weiner, 1989; Raine and Scheinberg, 1988). CD4+ T 
helper cells, subdivided according to the cytokines they produce i.e. T helper 1 (Th1) cells 
secrete proinflammatory cytokines such as interferon gamma (IFN-1), tumour necrosis 
factor alpha (TNF-a.) and lymphotoxin which enhance antigen presenting cell activation 
and help to clear intracellular pathogens and T helper 2 (Th2) cells on the other hand 
secrete cytokines such as inter1uekin (IL) 4, tl-5, and tl-13 that activate antibody class-
switching and eliminating blood-borne infectious agents (Bar-Or eta/, 1999), are the 
principal cell types involved. TNF-a. is found in plaques of MS patients being produced by 
astrocytes and macrophages, but not in non-MS sufferers (Bolton, 1997; Bar-Or eta/, 
' 1999). White matter damage is associated with CD4+ cells which enter the CNS, migrate 
to white matter and interact with local antigen presenting cells such as microglial cells i.e. 
the endogenous macrophages (Raine and Scheinberg, 19S8). CDS+ cells tater on 
downregulate the CD4+ mediated response (Raine and Scheinberg, 1988), however 
t CDB+ cells themselves may be responsible for disease initiation through the complexion 
~, of myelin peptides, myelin basic protein (MBP) and proteolipid protein (PLP) and myelin-
associated glycoprotein (MAG), with the HLA-A2-restricted CDS+ cell response 
(Giovannoni, 1997) through an MHC-1 cell response unlike the CD4+ cell mediated 
response, which is a MHC-11 cell response (Hafler and Weiner, 1989; Calder eta/, 1989; 
Oksenberg eta/, 2001). In MS patients' cerebrospinal fluid, fewer circulating CDS+ cells 
··• are found than in controls (Giovannoni , 1997) suggesting absence of the down-regulating 
effect. 
I 
l 
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In general the immune response associated with MS involves infiltration of activated 
CD4+ Th cells across the BBB, activation of these cells by APC to proliferate and 
produce cytokines. The antigen-T cell receptor-MHC complex with the help of co-
stimulatory pathways and specific cytokines initiate cell-mediated inflammatory reaction, 
which activates macrophages, microglia, astrocytes and possibly endothelial celts, further 
enhancing production of cytokines and recruitment of inflammatory cells. Inflammatory 
cells are recruited by chemoattractants such as eicosanoids, NO, and leukotrienes and 
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upregulation of adhesion molecule expression on endothelial cells. Recruitment of 
lymphocytes into the CNS across the BBB is achieved by the action of adhesion 
molecules some of which include intercellular adhesion molecule-1 (ICAM-1 ), intercellular 
adhesion molecule-2 (ICAM-2), vascular adhesion molecule-1 found on cerebral 
endothelial cells (VCAM-1), E-selectin (ELAM-1) and P-selectin (GP-140) and leukocyte 
functional antigen-1 (LFA-1), vascular leukocyte antigen-4 (VLA-4) and L-selectin (LAM-
1) found on various different leukocytes. The interaction/recognition between the ligands 
presented on the BBB cells and leukocyte facilitate the migration of the cells across the 
BBB (Vries eta/, 1997; Giovannoni, 1997). 
Cyclophosphamide, a drug that can penetrate the CNS, is one of the most effective 
immunosuppressants in MS patients (Calder eta/, 1989; Hatler and Weiner, 1989) and 
has been used for a long time. However, MS therapy is predominantly through the use 
immunosuppressive substances including steroids, (Hafler and Weiner, 1989; Bolton, 
1997; Fretland, 1992; Jacobs eta/, 1999) such as dexamethasone, cyclosporin-A and 
methotrexate, and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and 
aspirin (Fretland, 1992). Glucocorticoids have a very powerful anti-inflammatory effect but 
use in MS therapy fails to inhibit disease progression (Jacobs eta/, 1999). Interferon 
(IFN) which down-regulates macrophage production of cytokines and increased 
expression of glucocorticoid receptors has also been used in the treatment of MS (De 
Vries eta/, 1997; Jacobs eta/, 1999). MS patients treated with IFN-a exhibit reduced 
number of clinical exacerbations and significantly lower accumulation of disability 
characterisitics (Jacobs, 1996; Jacobs eta/, 2000). Vitamins B12 and D when included in 
regulated amounts in the diet improve prognosis in MS patients (Marnierni et al, 1998; 
Trojano and Paolicelli, 2001 ). Activated vitamin D i.e. 1 ,25-dihydroxyvitamin 0(3) (1 ,25-
(0H)(2)0(3)) has immunomodulatory effects on MSIEAE as shown by various studies 
(Muller et a/1995; Lemire et a/1995; Muller et a/1996; Jirapongsananuruk 2000; 
Boonstra et a/2001) as an immunosuppressant (Fukoka et a/1997; lssa, eta/., 1998; 
Oksenberg eta/, 2001). Vitamin D synthesis has therefore been proposed as a non-
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genetic aetiological factor in MS pathology (Oksenberg et at, 2001) a proposition 
supported by another proposition in which it is suggested that MS has a higher 
prevalence rate in latitudes where insufficient vitamin D is synthesized from solar 
sources. Vitamin D compounds (in particular 1,25-dihydroxyvitamin Da) are shown to be 
selective immunosuppressants and either prevent or significantly suppress disease in 
animal models of autoimmune disease. 
Zinc deficiency in the diet may also contribute toMS pathology (Harbige, 1996) due to the 
increased levels of the superoxide CuZnSuperoxide dismustase (CuZnSOD) (Cunane et 
at, 1994). It is thus necessary to ensure that adequate levels of zinc are supplied 
(Johnson, 2000). 
A study on the effect of fat consumption in the diet of MS patients showed that 
consumption of 20.1 g of fat and less as compared with consumption of amounts greater 
than 20 g was beneficial with only 31% dying and only slight deterioration while for those 
whose consumption was high, there was serious diSc'1bility (79%) and deaths (81%) 
(Swank and Grimsgaard, 1989). 
It has long been suggested that dietary therapy may improve fatty acid metabolism 
{Horrobin, 1979) and also that dysfunction in fatty acid metabolism may lead to 
biochemical changes in myelin and blood cells {Neu, 1985). Fatty acid metabolism is 
important because fatty acids are precursors to the prostaglandins, mediators ci immune 
reaction of inflammation and play an important rote in the maintenance of the CNS and 
the myelin sheath. They also maintain cell membranes and transport fats around the 
body. More recent work has suggested that proper nutritional intake of fatty acids may 
alleviate disease and improve health (Harbige, 1996; Timmerman and Stuifbergen, 
1999). In cell culture and animal feeding studies it has been shown that polyunsaturated 
fatty acids can influence lymphocyte proliferaton, the production of cytokines by 
lymphocytes and natural killer cell activity {Calder, 1993; Calder et at, 2002). The type 
and amount of fatty acid in the diet greatly affects the content of serum and spleen 
lymphocyte fatty acid content {Peterson et at, 1999; Jeffery et at, 1996; Jeffery et at, 
1997). EAE mice orally fed on plant lipid rich in the n-e fatty acid I.-linolenic acid from 
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Borago officina/is showed inhibited clinical incidence and histological manifestations of 
acute EAE, and the clinical relapse phase of chronic relapsing EAE (CREAE) was also 
markedly inhibited (Harbige eta/, 2000). Harbige and Fisher (2001) also showed that 
feeding fish oil rich in long-chain n-3 fatty acids decreased both T-helper (Th) 1- and Th2-
like responses. In contrast, borage (Borago officina/is) oil rich in n-6 poly-unsaturated 
fatty acids increased Th1-like responses but decreased Th2-like responses, and possibly 
enhanced suppressor cell or Th3-like activity. 
Modulation of the immune system in MS therapy has only small clinical benefrt and 
therefore it has been proposed that immunosuppressants used in therapy need to be 
facilitated access to the site of ongoing immune response (Calder et al, 1989). 
Many new and different treatments and therapies forMS are being tried, however, due to 
the fact that the cause of MS is to date unknown, effective therapy and cure of MS will 
evade us until we can better understand the underlying causes of MS. 
1.3. Experimental Allergic Encephalomyelitis 
Encephalitis is the inflammation of the brain. EAE is an autoimmune disease model is an 
important experimental tool because of its similarities to the human ailment, MS. The use 
of such animal models allows the study of the progression of the disease from inception 
especially well, given that the life span of the animals used (i.e. rats) is relatively short 
and the progression and development of the disease can be tracked in animals more 
readily than MS in humans, which has a longer period of manifestation. It Is important 
however to note that although there are many similarities between EAE and MS. 
important immunological differences do exist (Juhler, 1988), such as the fact that where 
as EAE is induced MS is not. 
Although highly reproducible, EAE is genetically restricted (Bolton, 1997; Paterson, 1976) 
requiring different agents to elicit the initiation of pathology in different species e.g. the 
strain-13 as compared with the Hartley guinea pig, Lewis rat compared with the Sprague 
Dawley and there are also differences among animals e.g. mice, rats, guinea pigs and 
primates (Paterson, 1976; Fretland, 1992; Toumier-Lasserve, 1993). Once EAE has been 
21 
initiated in an animal species, EAE may be transferred from one animal to another of the 
same species using T -cells, but not antibodies from the infected animal showing that EAE 
is a cell-mediated disease. EAE cannot be transferred from one species to another using 
T -cells probably because of the difference in the HLA/MHC genes of each animal 
species. 
1.3.1. Induction of Experimental Allergic Encephalomyelitis 
The most effective and rapid way to induce acute EAE in animals is by a single 
intracutaneous or footpad injection of central nervous system (CNS) tissue, usually 
incorporated into an immunologic adjuvant, which is commonly Freund's complete 
adjuvant (CFA) (Juhler, 1988). Freund's adjuvant is comprised of killed mycobacterium 
suspended in paraffin oil and emulsifying agent to ensure creation of a stable water-in-oil 
emulsion (Paterson, 1976; Bolton, 1990) and increases the efficacy of the toxin and in 
this case, accelerates the development of disseminated EAE. 
CNS tissue homogenates and extracts, used in the induction c:A EAE, show extraordinary 
stability. The encephalitogenic activity (ability to produce the encephalitis reaction) of 
whole CNS tissue is retained even after: boiling; autoclaving; autolysis; treatment with 
fonnalin, or acid or alkali; ultrasonic vibration, and repeated cycles of freeze thawing 
(Paterson (1976). That autologous, homologous, or heterologous brain or spinal cord 
can be used to induce EAE suggests that the encephalitogenic property of CNS tissue is 
attributed to organ specificity rather than species specificity. That is, the antigens involved 
are unique to the brain and spinal cord across different species. Thus although it is 
possible to induce EAE in an animal with the use of CNS tissue from another animal of a 
different species, it is not possible to use the T -cells of the EAE diseased animal to 
transfer the disease from one species to another. 
1.3.2. Course and Features of Experimental Allergic Encephalomyelitis 
The disease EAE occurs over a period of 3 weeks (21 days), with the height of disease at 
1Q-12 days post-induction and death following shortly within 5-7 days after this. 
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However, in the Lewis rat model, natural recovery without any pharmacological 
intervention may occur at around 21 days after inoculation (Paterson, 1976). The disease 
is "forward" progressing with signs exhibiting from the posterior end of the body towards 
the anterior i.e. the tail shows flaccidity then there is hind limb paralysis, fore limb 
paralysis, and finally cognitive/mental symptoms which may be followed by death. 
EAE is histologically characterized by perivenular foci of mononuclear cellular 
inflammation, primarily in the spinal cord and brainstem, and demyelination (Juhler, 
1988). Acute EAE shows demyelination in limited areas only and never in areas covered 
by cellular inflammation. The common clinical manifestations of EAE induced by the 
immune reaction are ataxic gait, paresis or paralysis of hind limbs, faecal impaction and 
urinary retention due to autonomic nervous system dysfunction from spinal cord injury, 
which appear within 10-21 days of induction with EAE (Paterson, 1976). 
1.3.4. The 888 in Experimental Allergic Encephalomyelitis 
Onset and progression of EAE involves both the cellular and humoral components. The 
interaction of the two components is important in EAE as evidenced by the fact that T cell 
subsets have regulatory influence on 8 cell activity, and humoral responses require 
action of both T cells and macrophages. T cells are the main agents in EAE and also in 
MS however, the suppression of B.-cell function leaving the T cell function intact prevents 
the development of EAE but does not stop cellular infiltration (Juhler, 1988). The 
activation of the T cell requires an antigen to be presented with the MHC by antigen 
presenting cells such as astrocytes, monocytes and endothelial cells. 
The 888 effectively keeps out humoral substances and immunoreactive cells. By 
providing an avenue through which cellular infiltrates that would have otherwi been 
excluded from the CNS by the 888 are allowed into the CNS, 888 breakdown plays an 
important role in disease initiation. 
That 888 breakdown is an initial feature of EAE is shown by the development of EAE 
lesions in the areas that "leak". Also, in Lewis rats it has been found that even before the 
infiltration of cells into the CNS appear during EAE, the blood protein fibrinogen exhibits 
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perivascular accumulation and persists along with and mixes with infiltrating inflammatory 
cells (Paterson, 1976), a sign of increased permeability of the BBB suggesting that there 
is a period between the breakdown of BBB function and the infiltration of inflammatory 
cells. The naturally permeable regions of the CNS, which circumvent the 888, may 
contribute to the degeneration of tolerance and play an important role in the pathogenesis 
of EAE. 
It has been suggested that vasoactive amines such as histamine, are possible mediators 
in the breakdown of the BBB. Vasoactive compounds stimulate the retraction of 
endothelial cells thereby increasing capillary permeability and allowing the infiltration of 
large sized serum proteins. Histamine is found in excessive amounts during early 
neurological disease, being released from mast cells it has an up-regulatory effect on 
pinocytic vesicle activity in neurovascular isolates, an action that enhances transport 
across the BBB up and above the norm in vivo. 
Prostaglandins cause dilation of blood vessels and are mediators in the process of 
inflammation suggesting that they may also play a part in the enhanced permeability of 
the BBB during disease. Prostaglandins of the E and F series have also been found in 
differentially increased amounts in CNS tissue from EAE animals and CSF of MS patients 
(Fretland, 1992). Nitric oxide (NO) which is vasodilatory and can be generated by the N-
methyl-0-aspartate (NMDA) receptor (Bolton, 1997) is also found in increased amounts. 
Cytokines such as such as interferon (IFN) and tumour necrosis factor (TNF), are 
1 
mediators of the immune response that interact with specific cell-surface receptors. 
Cytokines produced by leukocytes are interieukin, and those produced by lymphocytes, 
lymthokine. Cell derived cytokines lnterteukin -1 (IL-1) and TNF- a are found in 
increased levels in the CNS fluid of MS patients as compared to non-MS patients 
(Fretland, 1992) with levels of TNF- a found to correlate closely with gravity of 
neurovascular disturbances in MS patients with active disease. IL-1 and TNF have been 
1, shown to cause demyelination and lassitude (Fretland, 1992). 
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1.3.4. Immunotherapy of Experimental Allergic Encephalomyelitis 
The prevention and treatment of EAE is important because it gives insight into the 
mechanism and pathogenesis of MS. Two approaches to the treatment and prevention of 
EAE were suggested historically (Paterson, 1976). In the first, CNS tissue homogenate 
was injected into newborn animals that were later on assessed on their capacity to 
develop EAE with a CNS-adjuvant mixture. In the second approach mature animals are 
given a series of injections of CNS tissue homogenate or MBP, either incorporated in 
incomplete adjuvant or without carrier, prior to being challenged with CNS-adjuvant. In 
the first instance Wistar outbreed rats, inbred DA rats and Lewis-BN or Lewis-DA hybrids 
showed a decrease in their capacity to develop EAE when challenged with CNS tissue-
adjuvant at 8- 10 weeks of age. In the second instance, there was dramatic inhibition of 
EAE in adult rabbits given CNS tissue homogenates prior to spinal cord-adjuvant 
sensitisation possibly through acquired immunological tolerance (Paterson, 1976). The 
MBP rather than whole CNS tissue in guinea pigs, rats or monkeys, shows significant 
inhibition in EAE development, suggesting that MBP confers a broad base protective 
cover against development of disease. This may arise due to desensitisation of the 
animal's immune system to the circulating effector lymphoid cells (Paterson, 1976). The 
use of the two approaches given above suggests therapy and treatment in/for two groups 
of subjects. The first approach seems suitable for a population that may be exposed to 
predisposing factors to the development of MS i.e. an immunization of the young people 
in a population. The second approach seems suitable for an adult sub-population that is 
present in a larger population group having subjects with MS. 
Therapeutic control of EAE makes use of a number of drugs of which the 
immunosuppressive drugs are the most common. These include nitrogen mustard used 
in a disease model of guinea pigs, that shows decreased mortality and paralysis, and 6-
mercaptopurine which, when administered to rabbits, suppresses development of EAE, 
although on cessation of use, EAE symptoms recurred. In a rat model, a combination of 
6-mercaptopurine with duazomycin-A inhibited EAE development much better than 6-
mercaptopurine administered alone, and the inhibitive effect persisted even after stopping 
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drug administration. Cyclophosphamide injections gave an extended inhibition of EAE in 
guinea pigs (Peterson, 1987) showing that drug intervention is a viable control measure 
in the therapy of EAE. Also, injections of antilymphocyte serum have shown inhibition of 
EAE in rabbits and guinea pigs probably arising from the diminished production of 
lymphokines (Paterson, 1976). 
Corticosteriod treatment a few days after induction of EAE in particular delays 
development of disease and may even suppress it completely. The hormonal steroid 
oestrogen has a suppressive effect on development of EAE while progesterone actually 
appears to aggravate the symptoms, enhancing clinical neurological signs of the disease. 
The importance of EAE in the study of MS is evidenced by the similarities in both 
diseases. The initial occurrence in both diseases is dysfunction of the BBB leading to 
infiltration ofT -cells and macrophages actions that precipitate the development of lesions 
and cause neurological dysfunction. Substances that can cause disruption of the BBB 
integrity of through enhanced permeability or by causing physical breakdown such as is 
displayed by vasodilation, are important in the study of BBB pathology. 
1.4. L-Omlthine decarboxylase (ODC) 
1.4.1. Physical properties of L-Omithine Decarboxylase 
ODC is a key enzyme in polyamine (PA) biosynthesis (Murakami, 1994; Morris, 1991 ; 
Kumar, Butler, 1999) as the rate-limiting enzyme in the biosynthetic pathway of PA by 
catalysing the conversion of ornithine to putrescine (Baskaya, 1996). ODC is a 53 kDa 
dimer that is extremely labile, and occurs in relatively low levels in cells i.e. it has been 
estimated that there may be 100-200 molecules of enzyme in a quiescent cell , however 
levels are higher in active cells and in the blood, being in the range of 85 micromole per 
litre. ODC has a short biological half-life (Morris, 1991 ; Bernstein, Muller, 1999) estimated 
at 5-60minutes (Paschen, 1992), although the half~ife of ODC mRNA is considerably 
longer (Morris, 1991) suggesting that as ODC diminishes in concentration, new ODC may 
be produced. Ornithine is derived from diet supplement, metabolism in urea cycle or as a 
constituent of blood plasma while ODC is produced in response to various growth factors. 
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ODC has been shown in highest concentration in the smallest, most rapidly proliferating 
cells (Anehus, 1984) implicating it in cell development and growth. Immunocytochemical 
studies of various rat tissues showed high cytoplasmic immunostaining of ODC in 
epithelial cells of kidney, prostate, and adrenal medulla of testosterone-treated rats, in 
glandular epithelium of small intestine, and in pancreas of neonatal and adult rats 
(Schipper eta/, 1999). Other studies localisation studies of ODC in rat tissues in different 
cell lines show that that strongest staining for ODC was found in the nucleoplasm of 
mitotic cells, whereas confluent cells showed moderate perinuclear staining (Schipper, et 
a/., 1999). The main cellular locus of ODC in both the immature and adult central 
nervous system however is the neuron (Bernstein and Muller, 1999). 
1.4.2 Regulation of ODC under normal physiological conditions 
In normal conditions a careful balance between synthesis, degradation, and uptake 
maintains the optimum levels of ODC. There are various means of regulating ODCIPA, 
which include regulation of both the synthetic degradative arms of the PA biosynthetic 
cycle i.e. the regulation of ODC and the regulation of S-adenosylmethionine 
decarboxylase (SAMD). Furthermore, cells have an efficient transport system for 
utilization of exogenously derived PA. SAMD catalyses the formation of decarboxylated 
S-aclenosylmethionine an enzyme required for the metabolism of spermidine synthase 
that is necessary for the production of spermidine from putrescine (Bernstein, Muller, 
1999). The present study concentrates on the synthetic arm of ODC. 
The amount of ODC present in the cell is regulated by growth factors (which normally 
increase expression), and by polyamine interactions at the transcriptional and 
translational stage of the cell cycle and also by enzyme degradation (Suzuki, et at., 1994) 
where PA may bind with DNA and RNA Growth factors, hormones, regenerative stimuli , 
tumour promoters, immunoacljuvants and various drugs affect normal ODC activity. In 
adverse conditions associated with pathological insults, ODC activity is induced by 
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seizures, excitotoxic conditions, cerebral ischemia and instances of blood-brain barrier 
breakdown (Mustafa, et a/1996). 
ODC expression is mainly regulated post-transcriptionally (Rohn, eta/., 2001) although a 
transcriptional factor (Sp1) may be involved in neoplastic progression due to altered 
regulation (Kumar, Butler, 1999). The binding of transcription factors Sp1 and Sp3 may, 
dependant on relative amount and binding activities, has an important role in ODC 
regulation during epidermal tumour development (Kumar, Butler, 1999). 
Negative feedback regulation by the PA normally regulates ODC activity and degradation 
of ODC is accelerated by antizyme, an CDC-inhibitory protein induced by the build up of 
PA. ODC and antizyme forms an ODC-antizyme complex (Paschen, 1992; Murakami, et 
a/. , 1994; Seiler, Atanassov, 1994; Suzuki , eta/. , 1994) thus inactivating ODC. Antizyme 
also degrades ODC by a proteosome i.e. 26S proteosome and may function as a 
negative feedback regulator of polyamine transport (Suzuki , eta/., 1994) in addition to 
inactivating the enzyme by complexing. 
ODC expression and activity is responsible for the synthesis of PA, which have been 
shown to mediate in the breakdown and dysfunction of the BBB the initial action in the 
pathogenesis of MS and EAE. The obvious relationship between the enzyme ODC and 
synthesis of polyamines themselves suggest that regulation of polyamines through 
regulation of their rate-limiting enzyme may provide an avenue for prevention or therapy 
of MS. It should be noted however, that normal physiological processes are dependant 
on the synthesis and normal function of PA. Indeed any action to regulate or inhibit ODC 
and thus affecting polyamine synthesis and function y,uuld have to be well executed to 
produce the desired effect while yet not being of fatal consequence. 
28 
1.5. Polyamines 
Figure 1.1. showing the structure of the polyamines putrescine, spennidine and 
spennine. 
Putrescine 
H ~~N~NH2 
H2N N 
H . 
spennme 
PA spermine, spermidine, and putrescine are linear aliphatic molecules of small 
molecular mass (figure 1.1 ). All PA have positively charged amino groups at physiological 
pH that have steric and cationic properties and are thus water-soluble organic bases. 
One or more of the PA occur in every living cell and are dosely regulated according to 
the stage and state of growth. PA have a wide, but uneven, distribution in mammalian 
and non-mammalian tissues and cells. All have been found in eukaryotes while 
spermidine rarely occurs in prokaryotes. PA are ornithine-derived molecules with various 
roles whose precise function(s) in vivo have yet to be detennined (Cochet and Chambaz, 
1983; Koenig eta/, 1983; Oetken eta/, 1992; Mehta eta/, 2002). 
The best-known physiological function of PA is their interactions with anions such as RNA 
and DNA thus affecting cell growth, division and differentiation (Hoet and Nemery, 2000). 
At physiological concentration PA can condense DNA, chromatin and promote nsitions 
from B to Z DNA (Balasundaram and Tyagi, 1991). PA can modulate functions of RNA, 
DNA, nucleotide triphosphates, proteins, and other acidic substances by modulating 
phosphorylation. PA stimulate synthesis of special proteins and stimulate the assembly of 
30 S ribosomal subunits and regulate ion channels (Igarashi and Kashiwagi , 2000) and 
reduce the activity of cellular protein tyrosine phosphates towards endogenous substrates 
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(Oetken et af, 1992). A minimal level of PAis required for a cell to move from G1 through 
S phase and PA are directly involved in DNA synthesis (Balasundaram and Tyagi, 1991). 
One of the earliest events occurring during cell growth, replication and differentiation is 
the increase in PA (Koenig et at, 1983). Cell proliferation is associated with increased 
turnover of PA (Oetken et af, 1992), which seem to have a nutritional function in certain 
growing tissues and a role in tissue repair after injury (Bernstein, 1999). PA are also 
found in high quantities during cellular multiplication, differentiation and even 
regeneration. A change in the hydrogen bonding capacity of PA leads to a decrease in 
protein synthesis and growth rate i.e. cells in a polyamine deficient environment have a 
lower protein synthesis and growth rate (Balasundaram and Tyagi, 1991). In a rat model , 
oral feeding of spermine to pups (day 10-14) postpartum at elevated levels from that 
found in natural/physiological levels showed enhanced/advanced development of the 
small intestine (Buts et af, 1993). Progesterone modulates sperm function by stimulating 
biosynthesis of polyamine (putrescine and spermidine) (Calogero et af, 2000). 
In addition PA stabilise membranes and act as messengers of cell signals (Bernstein and 
Muller, 1999). PA modulate receptor action and signalling pathways such as in the effect 
of spermine on neuronal nicotinic acetylcholine receptors, which is a voltage dependant 
action and occurs when there is an increase In extracellular spermine (Haghighi and 
Cooper, 1998). PA interact with acidic amino acid residues lining and flanking potassium 
ion channel pores thus modulating their action (Lin et af, 1997). 
By binding to anionic sites, PA stabilize mitochondria (Toninello et af, 1985) possibly 
contributing to the homeostatic balance of Ca2• for which mitochondria operate as low 
affinity high capacity buffer systems. Koening eta/ (1983) from findings in their work 
suggest that polyamine synthesis is necessary for stimulation of membrane transport 
functions and PA serve as messengers to generate a Ca2• signal by increasing Ca2• 
influx and mobilizing intracellular calcium via a cation-exchange reaction. ODC is Ca2• 
dependant enzyme i.e. the production of ODC is upregulated by ea2•, and this is a 
suggested mechanism in the polyamine mediated BBB breakdown (Bolton, 1997). 
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PA play a role in remodelling the extracellular matrix (Stabellini eta/, 2002) by their 
interaction with proteins and may also facilitate cell death through a complex cascade of 
events (Thomas, 2001). PA are involved in neoplastic disorders. This is shown by the 
therapeutic effect observed by inhibition of polyamine uptake in such disorders (Seiler et 
a/, 1996). 
1.5.1. Polyamine Regulation 
Irregular spatial and temporal PA levels are detrimental to proper physiological body 
function. Adequate intracellular levels of PA are necessary for optimal growth and 
replication of all cell types. PA are normally sequestered suggesting that only free PA are 
physiologically active (Bernstein, eta/., 1999). Multiple pathways regulate cellular PA 
levels. PA can be synthesised from amino acid precursors, obtained through cellular 
uptake mechanisms that salvage PA, from the diet and intestinal microorganisms, and 
from stepwise degradation (Bernstein, Muller, 1999). The decarboxylation of ornithine by 
the enzyme ODC to form putrescine, which in tum is converted to spermidine and 
spermine, is the rate-limiting step in the biosynthesis of PA. 90% of the enzyme activity 
involved in PA synthesis is located in the cytoplasm (Baskaya, eta/, 1996). 
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Figure 1.2. The synthetic pathway of polyamine production. 
ornithine 
ornithine decarboxylase enzyme 
AcetyiCoA:polyamine N 1-acetyltrans rase spermidine synthase 
spermine synthase 
AcetylCoA:polyamine N 1-acetyltrans erase 
x = AcetyiCoA:spermidine N8-transferase, y = N8-acetylspermidine deacetylase 
Ornithine loses a molecule of carbon dioxide through the action of ODC. The action of 
AcetyiCoA:polyamine N1-acetyltransferase and polyamine oxidase (PAO) are responsible 
for interconversion of spermine to spermidine and spermidine to putrescine in the cytosol 
and AcetyiCoAspermidine N8-transferase (nuclear) and (7) N8-acetylspermidine 
deacetylase catalyse the interconversion in the nucleus (Seiler and Antanassov, 1994). 
Other enzymes not shown include serum albumin oxidase (SAO) that participates in the 
oxidative deamination of PA, the products of which are hydrogen peroxide, ammonia, and 
aldehydes and diamine oxidase (DAO), which is mainly cytosolic and re-sealeable (i.e. 
once released from the cell may be re-incorporated into the cell) may also produce 
substrates similar to that of SAO (Seiler and Antanassov , 1994). Inactivation of ODC 
leads to a depletion of intracellular PA. Depletion, release and catabolism of PA may take 
several hours. Putrescine levels are depleted first, followed by spermidine but spermine 
levels are not usually depleted. 
1.5.2. Polyamines and pathology 
Due to the important physiological roles of PA, a disturbance in the synthetic pathway 
would generate a number of deleterious effects. Dysfunction of the polyamine 
biosynthetic pathway, in particular increased polyamine production has been linked to 
ischemia (Baskaya, Rao, et a/1997; Shohami, Nates, et at, 1992), cancer (Thomas and 
Thomas, 2001; Kumar et at, 1999; Luk, Casero eta/, 1987), epilepsy (Bernstein and 
Muller, 1999), and of BBB breakdown. Cancer cells appear to be more dependant on PA 
because of their higher proliferative rate (Luk, Casero, 1987). 
PA can directly bind to DNA and thus modulate DNA-protein interactions. It has been 
suggested (Brooks, 1995) that at the start of S phase during the cell cycle, expression of 
PA leads to disruption of transcription and splicing, giving priority to DNA and histone 
synthesis in non-viable cells and may be a cause of autoimmunity (Brooks, 1995). 
Binding of PA to cell constituents has been proposed as a disruptive event to the 
regulatory feedback inhibition mechanism of PA synthesis (Davis 1990) leading to an 
accumulation of PA in the cell which can be toxic to the cell. Alterations in cellular 
polyamine levels may lead to apoptosis as a result of production of hydrogen peroxide 
during PA catabolism (Thomas and Thomas, 2001 ). 
An important aspect of dysfunctional PA activity is the effect on the BB8. Localized 888 
breakdown, vasogenic brain oedema induding abnormalities in neuronal function, and a 
reduction in local cerebral glucose utilization caused by focal cold injury of rat cerebrum 
are associated with a rapid biphasic increase in the concentrations of PA and their rate 
limiting synthetic enzyme ODC (Koenig eta/, 1989). In separate studies pharmacological 
antagonism of NMDA receptor has been shown to reduce polyamine levels, prevent BBB 
breakdown, and reduce EAE neurological symptoms (Bolton, 1997). 
Polyamines have been shown to mediate in the breakdown of the BBB, the initial event in 
the development of MS. They have also been shown to interact with DNA and also to 
facilitate DNA-protein interactions that may cause alteration in proteins to and initiate an 
autoimmune response by the formation of an antigenic protein or by causing breakdown 
in self-tolerance. 
1.6. Blood-brain Barrier 
1.6.1. Blood-brain barrier morphology and physiology 
The BBB is a complex structure the function of which is to impede the random movement 
of substances into the brain. It Is comprised of endothelial cells of the capillaries, 
perlcytes, microglia and astrocytes (figure 1.3). The endothelial capillary cells are 
completely surrounded by a basal lamina, in tum covered by astrocytic endfeet. 
Astrocytes, a distinct type of glial cell , support the neurons and are essential for the 
induction and maintenance of the endothelial cells. 
The BBB is highly dependent for proper function on the tight junctions of neighbouring 
endothelial (Bradbury, 1985; Bolton, 1997). The reduced number of pinocytic vesicles in 
the cells of the BBB also effectively restrict movement of substances across the BBB 
(Schlosshauer, 1993). Polymorphic and multi-branched pericytes control endothelial cell 
proliferation and are responsible for the regulation of vessel contractility and the synthesis 
and secretion of vasoactive compounds. The metabolic needs of the brain are met by 
specific transport systems of the BBB defined by the plasma membrane of the 
endothelium, which is similar in cytochemistry to an actively transporting epithelium 
(Bradbury, 1985). The passage of substances through the BBB is achieved through 
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passive diffusion, facilitated diffusion, active transport or transcytosis in coated vesides. 
Passive diffusion accounts for the passage of lipophilic substances although P-
glycoprotein actively exports specific lipid soluble molecules into the capillary lumen. 
Glucose, amino acids and ions are transported by facilitated diffusion by the action of the 
glucose transporter, other similar carrier systems, and ion pumps respectively 
(Schlosshauer, 1993). Still other proteins are transported across the BBB by transcytosis 
through the action of different endothelial cells e.g. iron is carried by transferrin 
(Schlosshauer, 1993), and small molecule nutrients (Pardridge, 1999). 
Figure 1.3. The structure of the BBB. 
Luman 
Nucleus 
AstrocytJ c Endfoot 
Tight JUnctiOn 
Schematic diagram of the functional BBB showing the tight apposition of astrocytic end-
feet, and the tight junction of the endothelial cells. (Modified from Schlosshauer, 1993.) 
Pathology involving the BBB results from disruption of the physical and physiological 
mechanisms responsible for the BBB's unique properties. 
Inflammation can cause BBB dysfunction. During normal function, mononuclear 
phagocytes and non-activated T -cells may be found in the CNS (Perry et. al., 1997). In 
human chronic inflammatory disease such as MS, lesions are dominated by large 
numbers of activated T -ceHs and macrophages (Perry eta/., 1997; Paul eta/., 2000; 
Rabchevsky, eta/., 1999) contributing to myelin and axon damage (Perry eta/., 1997). 
Similar pleocytosis occurs in EAE, however there is little evidence of significant 
demyelination or neuron damage (Rabchevsky eta/., 1999). 
MS is characterized by episodic malfunction of the BBB that allows oedema formation 
and inflammatory cell invasion of CNS tissue (Bolton, 1997), while in EAE neurovascular 
dysfunction is a prominent pathological feature. The mechanisms leading to the 
breakdown of the BBB in both MS and EAE are similar (Hawkins eta/., 1991) and the 
earliest lesions occur around the BBB (Pardridge, 1999). 
The mechanisms that lead to BBB dysfunction may be unknown but the dysfunction itself 
can be tracked and quantified (Rabchevsky eta/., 1999; Guerin eta/., 2001;Bolton, 1997; 
Koenig et al., 1992) along with the inflammation process (Paul et a/., 2000). PA have 
been shown to mediate the dysfunction of the BBB probably by increased production of 
PA (Koenig, Goldstone, Lu, 1989). 
The PA synthesis rate-limiting enzyme ODC thus presents an important point for the 
study of a mechanism that may be of use in the understanding of MS. In addition, MS 
therapy or treatment may be possible through the regulation of polyamines and the 
associated breakdown of the BBB, through the regulation of the enzyme ODC. 
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1. 7 Aims and Objectives of this study 
The course of EAE, from induction to recovery, lasts for a period of approximately 21 
days, with the height of symptom presentation at 10-14 days Pl. Accordingly, increased 
levels of ODC should be seen prior to, or at the height of, disease. Similarly the days pre 
and post day 13 PI EAE should exhibit lower levels of ODC. To test this proposition, a 
profile of ODC levels in the CNS tissue during the course of the disease must be carried 
out. 
This study compares the levels of ODC in EAE disease tissue at the height of disease, 
i.e. Day-13, with the levels of ODC in normal and recovering tissue for cerebellum, 
medulla and cervical spinal cord from Lewis rat CNS. Secondly, to establish a profile of 
ODC expression and location during EAE disease in the tissues exhibiting altered 
enzyme levels and ascertain if there is differential expression of ODC between 
cerebellum, medulla, and cervical spinal cord. In so doing, the present study will be able 
to determine the relative amount of ODC in these three tissues during EAE in the Lewis 
rat. The techniques developed and used included an appropriate protein assay, SDS-
PAGE and Western blotting. During the course of this project, problems were met with in 
the homogenisation of tissue and the protein assay therefore a signifteant part of this 
study was dedicated to this. There were also problems with sectioning and staining tissue 
for immunohistochemical and this was not carried out to completion. 
2.0. MATERIALS AND METHODS 
At the start of this project it was necessary to first establish the techniques that would 
later be used to achieve the aims and objectives of the study. In order to establish and 
verify this methodology, pig brain tissue samples were used. The pig brain tissue 
samples were available in large quantity, readily obtainable, and easy to handle and 
process for use in experimentation. As the establishment of the necessary technique was 
a process that required numerous experimentation trials, large amounts of sample tissue 
were required. It was not possible to use rat brain tissue from the animal model of EAE 
that was being assessed I.e. Lewis rat model, because this tissue was available in limited 
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quantity only and was not easily obtainable because of scarcity of both the tissue itself 
and the funds to acquire the tissue. It was not possible to use human tissue either, as 
human tissue is quite hard to obtain and extremely valuable. Also, the use of hl.HTlan 
tissue would have required getting pennission from various health and ethics committees 
and would have also necessitated the use of more stringent handling and usage control 
measures. However, once the techniques required for assessment of the tissue had been 
established, sufficient amounts of Lewis rat EAE tissue samples were available for 
experimentation. 
It was necessary to evaluate two techniques of homogenisation of the rat tissue to be 
assessed because in the first technique the yield of total sample was low. For a tissue 
sample of 200 rng a sample volume of about 2-3 ml was obtained. This was an equivalent 
to approximately 65-100 mg/ml of which only 10% was protein. Such low yield in total 
sample was inefficient for the quantity of rat brain tissue samples at hand and if this 
homogenisation method had been used the tissue samples avaHable would not have 
been sufficient for experimentation. The second homogenisation method (Min, editor, 
1999) assessed produced greater volumes of protein from each sample (4-6 ml as 
compared to 2-3 ml for method one) for subsequent assaying. 
Once an appropriate homogenisation procedure had been established, the next phase in 
the project consisted of establishing an appropriate assay for estimation of protein 
quantity within the homogenised sample i.e. tissue supernatant. Three different assay 
methods i.e. BioRadTM, Lowry and Bicinchoninic Acid (BCA) methods were used because 
during the experimentation it was discovered that some of the assays were incompatible 
with reagents used in the preparation of the homogenisation medium. The BCA method 
was finally chosen as the method for use in the analysis of the rat brain tissue 
supernatant because it proved the most efficient in tenns of accuracy and consistency in 
reproducing similar results. 
In chapter three, the problems and solutions to these problems, leading to the decision of 
which assay should be used, will be discussed in detail. 
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2.1 Animal tissue 
The for induction of EAE in animals and subsequent preparation of tissue was canied out 
at the John Harvey Research Institute, UK, by other research staff at the university using 
the method of Bolton and Flower, 1987; Bolton and Paul, 1997; Paul eta/, 2000. Tissue 
collected consisted of normal Lewis rats and CFA treated rats at day-13, EAE rats at day-
13 post inoculation (PI) and day~21 PI, the latter two representing the height of dlnical 
manifestation of disease and early recovery of the rats respectively. Three animals each 
of normal, CFA-treated, day-13 and day-21 PI EAE were used. The tissues were stored 
at -70° C. The weights of the rat brain tissues are given in appendix I. 
2.2 Homogenisation of Protein 
Tissue was solubilised in preparation of electrophoresis and Western blotting. 
Homogenisation releases and solubilises the proteins for easier analysis. During the 
study it was found that the first homogenisation method used produced a low yield of total 
sample volume (2-3 ml) and the efficiency of solubilisation was circumspect. As the brain 
samples available for analysis were in limited quantity, this method had to be replaced 
with a more efficient method for higher yield. 
A second homogenisation method produced a higher yield of total sample, in the range of 
4.5-8 ml i.e. effectively 2-3 times more total sample. The second homogenisation method 
used was an enhanced method for solubilisation of membrane proteins. Due to financial 
constraints, brain tissue available was shared with a colleague doing work on a 
membrane protein. However, the fact that the homogenisation method was particularty 
good for solubilisation of membrane proteins did not make it any less viable for the 
homogenisation of the protein that this study was looking to analyse i.e. ODC. 
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2.2.1. Homogenisation Method One 
Preparation of reagents. 
All reagents were obtained from Sigma-Aldrich unless otherwise stated and all equipment 
was properly sterilised induding autodaving where appropriate. Protease inhibitors 
leupeptin and pepstatin (Sigma, UK) were available in 100 mM concentration prepared by 
colleague. 100 mM ethylenediaminetetraacetic acid (EDTA) was prepared by dissolving 
37.22 g of EDTA powder in 1.0 ml of double distilled water (ddH20) in an Eppendorf(s). 
EDTA was then aliquoted into 100 Jll volumes in Eppendorfs and kept on ice for 
immediate use or stored at 200C. 100.0 mM N-(2-hydroxyethyl)-piperazine-N-2-
ethanesulphonic acid, sodium salt (HEPES) (pH 7.5) was made by dissolving 23.83 mg of 
HEPES pollllder in 1.0 ml of ddH20 then aliquoted into 100 Jll volumes and kept on ice for 
immediate use or stored at 20°C. Phenylmethylsophonyl fluoride (PMSF) was purchased 
at 200 J.1M concentration and stored at 20°C until required for use. 100 mM NaCI was 
prepared by dissolving 0.2922 g of NaCI crystals in ddH20 in a sterile 20 ml universal. 
Procedure 
The procedure used was that of Bolton et al (1990). Tissue sample was removed from 
storage at -700C and put into a 20 ml universal while still frozen for easier handling and 
thavved on ice. Individual tissue was cut up in 0.5 ml of homogenisation medium 
(containing 10 mM HEPES, 5 mM EDTA, 200 J.1M PMSF, and 100 mM NaCI) per 100 g of 
protein to be homogenised using dissection scissors. 
A homogenate was prepared by equal and repeated aspiration using sterile 1 ml syringe 
fitted with 21 and 19 gauge needle. This was followed by three cydes of freez-thawing, 
aliquoted In 1.2 ml volumes and centrifuged at 4°C in a HAWK Sanyo refrigerated 
centrifuge at 200 x 100 g for 30 minutes. The supernatant was then pi petted off and 
aliquoted into sterile Eppendorfs in 150 Jll volumes. The supernatant was then placed on 
ice ready for immediate use or stored at -sooc for use when required. The pellet was 
stored in aliquots at -20°C. 
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2.2.2 .Homogenisation Method Two 
The preparation of reagents and homogenisation of proteins was carried out on ice as for 
method one. 
Preparation of reagents. 
Protein Inhibitors leupeptin and pepstatin were available In ready to use concentrations 
(prepared by colleagues) of 200 mM and 100 mM respectively. 50mM NaCI was prepared 
in a 20 ml universal. The EDT A and PMSF were prepared as described in method 1 (p 
54). One molar (1M) homogenisation medium II was prepared using Tris-HCI powder in 
ddH20 and the pH of the resulting adjusted to 9.0 by titration with concentration 
hydrochloric acid (HCI) (Anachem). A 10% wlv SDS solution was prepared in ddH20 
using 5.768 g of SDS powder was weighed out in a fume cupboard using Metler Toledo 
scale into a 20 ml universal. A 20% vlv concentration of Triton X-100 (Sigma) was made 
by dissolving 100 Ill of Triton X-100 in 400 Jll ddH20, the dilution making it easier for 
dissolving in sample. 
Procedure 
Tissue was cut up in 0.5 ml homogenising medium per 100 g tissue in 20 ml universal on 
ice. PMSF, EDTA, and protease inhibitors leupeptin and pepstatin were added to give 
final concentration of 0.5 mM, 2.5 mM, 1 ~g/J.ll, and 1 ~g/~1 wlv respectively. SDS was 
added to a final concentration of 2% of total volume. Finally, Nacl was added to a final 
concentration of 200 mM. 
The homogenised sample was then placed in boiling water for 5 minutes, centrifuged at 
4°C in a HAWK Sanyo refrigerated centrifuge at 200 x 100 g for two hours, the 
supernatant pi petted off the pellet into Eppendorfs in 1.5 ml aliquots and to this was 
added 20 % vlv Triton X-1 00 to make up 2"Al of the total volume. The sample was then 
mixed on vortex and stored. 
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2.3. Protein Estimation 
To ensure that equal total protein is loaded onto gets and thus carry out accurate SDS-
PAGE and Western blotting, it is important to know the protein concentration of the 
sample to be assessed. This is achieved using a protein assay. Initially, the BioRad™ 
assay based on the Bradford method was used. This assay however gave inconsistent 
results over varying dilutions of sample (table 3.2 page 71) and numerous replications 
and so a second assay method, the lowry assay method was used. 
The timing required in the lowry assay for both the addition of reagents and mixing of 
samples, is intricate and may contribute to inconsistencies in this assay (Smith, et al, 
1985). The lowry assay method was also inconclusive in the assessment of protein 
content because it also gave inconsistent results over varying sample dilutions and 
numerous replicates (tables 3.5 and 3.6 page 76). For this reason a third protein assay, 
the BCA method, was assessed. The BCA method copes with higher levels of interfering 
agents and detergents than either the BioRad ™ or lowry assay methods (Smith, et al, 
1985). 
2.3.1. BioRad™ Protein Assay 
The assay method used with the BioRad ™ protein assay kit is based on the method 
described in Bradford et al., (1976).1n this method, the maximum absorbance for an 
acidic solution of Coomassie Brialliant Blue G-250 dye shifts from 465 nm to 595 nm 
when bound to a protein. The BioRad ™ is more compatible with a wider range of 
detergents than the original Bradford method. 
A stock solution of concentration 1 mglml of bovine serum albumin (BSA) was prepared 
in 25 ml universal. The BioRadTM reagent (BioRad ™> was prepared by diluting 1 :4 in 
water. Volumes 0.0 J,ll (zero blank), 1.0- 5.0 J.d, were pipetted into a 96 well microtitre 
plate in duplicate and made up to 5.0 J.LI each using ddH20. 200 Ill of BioRad™ reagent 
was then added to each well and the microtitre plate was shaken by hand and left 
standing for 5 minutes. The absorbance was read using a Rosys Anthos II 
spectrophotometer at 595 nm, corrected for the zero blank, and the results plotted with 
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absorbance/volume of sample used. The protein concentration was calculated from the 
standard curve. 
2.3.2. Folin Phenol Method (Lovvry Assay). 
The Lovvry assay is based on the biuret reaction in Vtlhich a protein placed in an alkaline 
system containing Cu2+ ion fonns a coloured complex with the peptide bonds. The Lovvry 
assay works in a two-step nature, a reduction of Cu2+ to Cu+ at the complexation site on 
the protein followed by reaction of the Cu+1 with Folin-Ciolcalteau reagent to form the final 
intense colour (Lovvry, 1955; Smith, eta/., 1985). 
Preparation of reagents 
The reagents 2% (w/v) hydrated copper sulphate (5H20), 4% (w/v) sodium potassium 
tartrate, 3% (w/v) sodium carbonate in 0.2 M sodium hydroxide were prepared fresh. 
Folin and Ciocalteu's phenol reagent was bought in ready-to-use concentration 
Absorbance at 640 nm was read on a visible light spectrophotometer (CeCil CE 2021). All 
reagents were supplied by Sigma. 
Procedure 
A solution of 1 mg/ml of the BSA standard was prepared. Triplicate volumes of sample 5-
50 fll were pipetted into Eppendorfs and the volume of each aliquot made up to 200 fll 
with buffer. The same was done for BSA. At the time of assay, 1 ml of copper sulphate 
solution was mixed with 1 ml of tartrate solution in a 100 ml beaker to Vtlhich 48 ml of 
freshly prepared 3% (w/v) sodium carbonate in 0.2 M sodium hydroxide was added. 1 ml 
of the final solution was added to sample and BSA The mixture was shaken and left to 
stand for 10 min at room temperature then 50 f..L1 of phenol reagent added to each. The 
mixture was again shaken and left to stand for 25 minutes at room temperature. After the 
25-minute incubation the solution was mixed again and 5 min later the absorbance of 
each sample and standard was read using CeCil CE 2021 spectrophotometer, at 640 nm 
using the water blank to zero the spectrophotometer. The mean for each sample's 
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absorbance was calculated, plotted with absorbance/volume and concentration of the 
sample calculated from the plot using a linear regression from the BSA standard curve. 
2.3.3. Bicinchoninic Acid (BCA) Assay Method 
BCA is a stable water-soluble sodium salt capable of forming an intense purple complex 
with cuprous ion (Cu 1+) in alkaline environment. This colour increases in a proportional 
fashion over a broad range of increasing protein concentration The BCA method shows 
greater tolerance of the bicinchoninate reagent toward interfering substances such as 
non-ionic detergents and simple buffer salts (Smith, et at, 1985; BCA Assay kit, Pierce 
Endogen). 
Procedure for BCA Protein Assay using the Microtitre Plate method. 
BSA standards with differing concentration 0.0 - 2.0 J.l.g/J.i.l were prepared in water from 2 
J.l.g/J.i.l stock provided with the kit following the instruction of the BCA Reagent Kit. 
Concentration of 10- 100% of homogenised tissue was made in water. 25 J.i.l of each in 
triplicate of the BSA standards and samples was pi petted into wells of a 96 well microtitre 
plate. BCA working reagent (WR) was made up with 1:50 solutions A:B of which 200 J.i.l 
were added to each well , the plate shaken, covered and left at room temperature for 2 
hrs. The absorbance was read at 570 nm on spectrophotometer (Rosys Anthos Hil l) and 
analysed using STINGRAYTM application software. Absorbance values were corrected for 
blank and plotted against standard curve and a calculation of protein concentration made 
using a linear regression equation (figure 3.8 page 80). 
2.4. Sodium Dodecyl Sulphate Poly-Acrylamide Gel Electrophoresis (SDS-PAGE) 
and Western blotting. 
The Western blotting technique is a semi-quantitative technique for assessment of 
specific protein contained within a sample. Proteins were separated by gel 
electrophoresis and were transferred to a nitrocellulose membrane then incubated in 
antibody (primary) raised against the antigen, followed by a second incubation an 
antibody (secondary) raised against the primary antibody and which Is also conjugated 
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with horseradish peroxidase (HRP) enzyme. The HRP is allowed to react with a 
chemiluminescent substrate that luminesces blue light at the sites at which the primary 
antibody is bound. The light is detected by film sensitive to blue light and developed. This 
film is assessed by densitometry of the bands of the specific protein. 
Samples were removed from storage at -20°C and thawed on ice. Samples containing 15 
J.l.g of protein were prepared. A four times concentration of Laemli sample buffer was 
added to the tissue sample to make up one third of the final volume, i.e. 10 J.LI, and the 
solution made up to a final volume of 30 J.l.l with water (Laemmli , 1970). The samples 
were mixed on vortex and placed in boiling water for 5 min then loaded onto the 
polyacrylamide gels for electrophoresis. 
Preparation of reagents. for 12% Resolving Gel. 
The gel-casting module was set up as per kit instructions (BioRad TM) on a flat surface. 
10% Ammonium persulfate (APS) (Sigma) was prepared i.e. 0.26 g of APS crystals in 
2.34 g of ddH20. 10% SDS was available ready-t<ruse. 25 ml of 12% resolving gel was 
prepared i.e. 3.55 ml ddH20, 2.5 ml 40% Acrylamide (Sigma), 3. 75 ml 1 M Tris-Base pH 
8.8, 1 OOJ.LI of 10% SDS, and 1 OOJ.LI of 10% APS. 1 OJ.LI of TEMED (Sigma) was added, the 
mixture shaken and poured into the gel-casting module to a level approximately 2 em 
from the top of the plates. A layer of H:P saturated isobutanol was applied to the top of 
the resolving gel to prevent extended polymerisation allowing the gel to set with a straight 
surface. The gel set for 20 min after which the H20 saturated butanol layer was blotted off 
using Whatman absorbent paper. 
5% Stacking Gel 
15 ml 5% stacking gel was prepared by mixing 3.64 ml of distilled water, 630 J.l.l of 40% 
acrylamide, 630 J.LI of 1M Tris-Base pH 6.8, 50 J.l.l of 10% wlv APS, and 50 J.LI of 10% w/v 
APS. 10 J.l.l of TEMED (Sigma) was added the mixture swirled and poured into the gel-
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casting module. The gel combs were inserted into the gel immediately on pouring in the 
stacking gel and the gel was left to set for 30 minutes. 
Laemmli Sample Buffer 
20 ml of Laemli sample buffer was made up by mixing 7 ml of ddH20, 4 ml of 10% SDS, 4 
ml of glycerol (Amersham, UK) ultra grade, 5 ml of Tris--Base pH 6.8, and 40 mg of 
bromophenol blue. The solution was mixed thoroughly with a vortex machine. 
ODC solution 
The preparation of ODC solution was carried out on ice. The L-ODC (Sigma) was 
removed from storage at -20°C and 0.762 x 103 g of powder was weighed out into 
Eppendorfs. 500 f.ll of water was then added, and then the solution was mixed on a 
''whirly" mixer and then aliquoted into 15 x 30 f.ll volumes, which were stored at -20°C for 
later use. The concentration is 1.538 IJg/IJI. 
The prepared gels are mounted in the Novex® gel electrophoresis module. A one times 
strength gel running buffer was poured between the two gels mounted in their glass 
plates to overflow at the tops of the plates. Using gel-loading tips, the boiled samples 
were loaded onto the wells as follows, 8 llg ODC solution, and 15 llg each of normal, 
CFA treated, Day-13 EAE and Day-21 EAE cerebellum, medulla pons, or cervical spinal 
cord and molecular weight marker. An example of the gel-loading pattern for an SDS-
PAGE analysis is given in figure 2.1a. and 2.1b. pages 46 and 47 respectively. 
Figure 2.1a Gel loading pattern for SDS-PAGE of rat brain sample 
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The figure above shows the layout of tissue samples for an SDS-PAGE analysis of rat 
brain sample used in the western blot. 
In later experiments the molecular weight markers was loaded in well separating the tYtU 
CNS tissue types i.e. tissues were loaded as, positive control , normal, CFA treated, Day-
13 EAE, Day-21 EAE, molecular weight marker, normal, CFA treated, Day-13 EAE, and 
Day-21 EAE (figure 2.1b pg 56). The molecular weight marker was in a position in which 
easier comparison could be made with respect to each tissue type in the different wells. 
Figure 2.1b Gel loading pattern for SDS-PAGE of rat brain sample. 
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The figure shows loading of samples onto gel with molecular weight marker separating 
CNS sections. 
Electrophoresis was carried out at 80mAmps in a Novex® X Cell II Blot module 
connected to an Anachem ScotLab electrophoresis power supply for 75-90 minutes after 
which transfer onto the nitrocellulose was accomplished using the wet transfer method as 
follows. The glass plates were seperated leaving the gel flat on one plate and the 
stacking gel cut off. Hybond-C nitrocellulose (Amersham, UK) and tYtU pieces of gel-sized 
blotting paper pre-wetted in transfer buffer were placed on top of the gel with the 
nitrocellulose in contact with the gel. Tv.u pieces of pre-wetted blotting paper were placed 
on the other side of the gel. 
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Figure 2.2 Protein transfer sandwich for transfer of protein from gel onto 
nitrocellulose showing arrangement of components • 
•••.•.••.....••.•...••....•.•••...•.••....•••.....••....••••...••••....•••....••••...•••• 
••....••.....•.....•••.....•.•...........•••....•.••...••••....•••....•••••..••••••.••••• 
.......................••.....•.....•........•........................................... 
....................................•.•.....•............................................ 
Ill !IIIII!! Ill! = Electrophoresis pad ••,___-•• = Nitrocellulose membrane 
e e = Blotting paper I:::; : ; : ·:::;:I = Polyacrylamide gel 
The transfer cassette was placed in the_Novex® X Cell II Blot module and filled with 
transfer buffer inside and tap water outside then placed in an ice bath. Transfer was 
carried out at 200 mAmps for 80 minutes using an Anachem Scotlab electrophoresis 
power supply._The transfer efficiency was tested using Ponceau S (Sigma) bought as 
ready-to-use solution, for visualisation of protein bands then washed off in three 5-minute 
washes of 20 ml of (0.1% vlv) PBS T\Neen-20. The nitrocellulose was then bathed in 20ml 
of blocking buffer, prepared by dissolving 5% wlv Marvel (Premier Brands, UK Ltd) non-
fat dried milk powder in PBS T\Neen (polyoxyethylene sorbitan monolaurate), on a plate 
rocker for 1 hour at room temperature to block non-specific binding of the primary 
antibody then placed in primary antibody (monoclonal mouse a.-ODC, Sigma; 1 :400), 
prepared in (0.1 o/o vlv) PBS T\Neen-20and incubated at 4°C overnight. The nitrocellulose 
was removed from the primary antibody solution and washed three times for 5-minutes 
each time in 20 ml volumes of PBS T\Neen then placed in secondary antibody (goat anti-
mouse, lgG Peroxidase conjugate, Sigma; 1 :4000) at roorn temperature for 1 hour on a 
plate rocker. 
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2.5. Enhanced Chemilurneniscence 
The membrane was then washed in PBS Tween solution and the excess solution blotted 
off. The nitrocellulose was then placed on a strip of cling film place on a flat v;ork.bench 
with no air bubbles trapped underneath. The surface of the nitrocellulose with the 
transferred protein was flooded with ECL reagent (Santa Cruz) prepared by mixing equal 
volumes of reagents A and B provided as part of ECL kit. The excess ECL reagent was 
drained off and the nitrocellulose was wrapped in cling film, taking care not to allow air 
bubbles to form, and was placed in a film cassette (Kodak) and exposed to light sensitive 
Kodak GBX film for 5 minutes. The film was then developed in a darkroom by bathing the 
film in Kodak GBX developer solution as directed by kit (Kodak GBX. UK) i.e. 5 minutes 
in developer then 8 minutes in fixer then film was then removed and allowed to air dry. 
2.6. Analysis of Gels 
The film was scanned with an Epson Twain scanner with Adobe Photoshop 5 software 
and densitometry of bands analysed using Gel-Pro Analyzer software. Densitometry 
values were used to plot graphs in Microsoft Excel®, with relative absorbance against 
tissue types as shown in results section. 
2.7. Statistical Analysis of Results 
The densitometry analysis gave a relative comparison of the optical density of the protein 
bands. The values obtained were analysed for significance using a one-way analysis of 
variance (ANOVA) with the variation arising due to point in disease course i.e. normal 
(day 0), CFA treated (control), day-13 EAE PI, and day-21 EAE Pl. 
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3.0. STANDARDISATION OF PROTEIN ASSAY 
3.1. Protein Assay 
The protein assay is used to detennine concentration of a solution. The choice of protein 
assay depends on various factors, an important one being presence of substances that 
interfere and thus distort the result. Initial stages of this study established an appropriate 
protein assay because the Western blotting technique relies on the proper detennination 
of protein concentration i.e. the results obtained by Western blotting are based on the 
assumption that the total protein content of each sample loaded the same. HOYJeVer 
establishing an accurate and reliable protein assay proved more difficult than expected, 
due to problems detailed in the following sections. 
BSA that was readily available and was easy to prepare and store was chosen as protein 
standard. A 1.0 ~g/J.t.l BSA was made as described previously and used to plot a standard 
curve. The protein assay methods assessed were the Bradford assay method 
(BioRad™), the Lowry assay method (Folin Phenol method) and the BicinchoninicAcid 
(BCA) method. 
3.1.1. Bradford Assay 
In assessing the Bradford assay, BioRad™ kit and protocol were used. This assay 
method is easy to use and the reagents and equipment required for its use were readily 
available. Using BSA (1.0 ~g/J.tl) for concentration 0.0- 2.0 J.lg /f.ll a standard curve was 
plotted. This is shown in the standard curve achieved in figure 3.1 below. 
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Figure 3.1 Standard curve for absorbance achieved per unit protein measured 
using bovine serum albumin (1 J.Lg/J.LI) as protein standard using the BioRad™ 
(Bradford) assay 
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Standard curve of BSA (1.0 J.L91J.LI). Plots are mean± SEM for n = 3. (Appendix IV shows 
data). The figure shows a good relationship between protein concentration and 
absorbance with little deviation. The plot provides a linear regression equation from which 
the protein concentration of samples may be calculated. 
Assay of prepared ODC solution 
As ODC was the protein to be assessed in the rat brain tissue, an assay was carried out 
to determine the effects of the assay on ODC. ODC was processed using homogenising 
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method II. Volumes of the prepared solution (concentration 1.538 tJg/fJI) ranging from 0-
15 J.tl were assayed using the BioRad ™ method and the absorbance achieved measured. 
(Table 3.1 below shows result and data is given in appendix V). 
Table 3.1. The protein concentration calculated for ODC sample on a BSA standard 
curve measured using BioRadTM assay. 
Linear regression equation for protein calculation, y = 0.0799x. 
Volume of Absorbance at Protein concentration Concentration 
sample (p.l) 570nm (J.tg/J.I.I} corrected for sample 
volume (JJ.g/UI) 
0 0.000 0.000 0.000 
3 0.829 10.375 3.458 
5 1.049 13.129 2.626 
6 1.191 14.906 2.484 
7 1.253 15.682 2.240 
8 1.315 16.458 2.057 
10 1.337 16.733 1.673 
15 1.415 17.710 1.181 
As sample volume increased protein concentration determined increased. The table 
shows an inconsistency in the protein estimation at~er the range of volumes of sample 
taken with most volumes of sample showing a higher protein concentration than the 
known concentration of 1.538 fJg/tJI. 
The differences between the known protein concentration of 1.538 JL9/J.tl and the 
calculated protein concentration are too large to be attributed to experimental error, 
suggesting that there is interference with the assay probably arising from substances 
within the homogenising medium. Further experimentation, using ODC sample of 
volumes ranging from 5-15 JJ.1 gave results that failed to tally with the known protein 
concentration of 1.538 J.tg/JJ.I. A table showing the results of such experiments using the 
BioRad™ method is given below (Data shown in appendix VI). 
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Table 3.2 Protein estimation for ODC solution assays 
ODC solution Expected Replicate One Replicate Two 
Volume assayed concentration Estimated protein Estimated protein 
bd) (11Qll11) (llg/111) (11Qll11) 
5 1.583 2.626 4.008 
10 1.583 1.673 2.339 
15 1.583 1.181 1.607 
Duplicate assays of ODC solution of known concentration showed inaccurate protein 
concentration detennination again suggesting interference. (Data shown in Appendix VI). 
Use of Pig Brain in protein assay standardisation. 
The standardisation of the techniques required the use of a large amount of sample 
meaning that large volumes of rat brain sample would be required. Rat brain sample was 
in limited quantity and not readily available therefore pig brain, which was readily 
available, was used in ear1y stages of this study. Initial experiments performed on 
undiluted pig brain sample (data not shown) showed that the homogenised undiluted 
sample was too concentration and the absorbance being out of the range of the standard 
curve. Subsequent assays were carried out at lower concentration as shown below 
(figures 3.3 and 3.4). 
A 1:10 dilution of pig brain sample in homogenising medium was assayed using the 
BioRad TM method and this was compared with an assay of 1:1000 of pig brain sample in 
homogenising medium also using the BioRadTM method. 
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Figure 3.2. Absorbance achieved for protein assay of pig brain sample for a 1:10 
dilution plotted against volume of sample using the Bradford method. 
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The protein concentration was calculated from a 1:10 dilution using the BioRad "™ method 
and a linear regression equation of an assay of BSA standards (1 J.Lg/J.LI concentration). 
The BSA standards 'o'lt"ere assayed for volume ranging from 0.0-7.0 J.LI (Data shown in 
appendix VIII). 
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Figure 3.3. Absorbance achieved for protein assay of pig brain sample 'for a 1:1000 
original dilution in water against volume of sample using the Bradford method. 
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The protein concentration was calculated from a 1:1000 dilution using the BioRad TM 
method and a linear regression equation of an assay of BSA standards (1 !J.QI!J.I cone}. 
The absorbance values seen are less than those for 1:10 dilution in figure 3.2. The 
7 
decrease is however not proportional to dilution. The graph seems to level of about 0.02 
nm, which may denote a saturation of sample however, in the 1 : 1 0 dilution it is seen that 
even above this concentration a linear plot can be achieved. (Data shown In Appendix 
VIII). 
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From figures 3.2. and 3.3. it can be seen that the lower concentration, i.e. higher dilution, 
is more affected by interference. Also, the absorbance values obtained from the lower 
concentration in figure 3.3. plateau at approximately 0.02 nm while in figure 3.3, the 
absorbance values reach a maximum of approximately 900 suggesting that this plateau is 
erroneous as supported by the point at 0.03 nm for 7 f.ll. 1:10 dilution was better for use in 
protein concentration calculations, because the absorbance values were in the range of 
BSA standards curve and were well distributed at the middle of the curve and thus, 
experiments were carried out to assess the amount of protein in the pig brain 
homogenate sample at an initial dilution of 1:10 in water. 
Figure 3.4. Absorbance achieved for protein assay of pig brain sample for a 1:10 
dilution in water against volume of sample using the Bradford Method. 
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Pig brain sample diluted 1:10 in homogenising medium shows that there is a direct 
proportional relationship between the concentration of the sample and the absorbance 
achieved. The result of this experiment also shows that the protein assay is working 
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within a small range and frts well within the working range of the BSA standard curve. The 
calculated protein content is shown in table 3.3, page 84. 
Table 3.3 Protein estimation for a pig brain sample diluted 1:10 in homogenising 
medium using the BioRad™ assay. 
Linear regression equation, Y = 0.422X 
Volume of BSA Absorbance at 
(J.LI) 570 nm 
Protein concentration 
(taking into account 
dilution) (~g/~1) 
Protein concentration 
corrected for sample 
volume (JJ.g/~1) 
1 0.091 
2 0.214 
3 0.689 
4 0.472 
5 0.568 
6 0.865 
7 0.829 
2.156 
5.071 
16.327 
11.185 
13.460 
20.498 
19.645 
2.156 
2.536 
5.442 
2.796 
2.692 
3.416 
2.806 
Table 3.3 shows the protein estimation for BioRad™ assay performed on different 
volumes of a 1 : 10 dilution of pig brain sample based on a BSA standards curve. The high 
concentration values obtained for volumes 3 and 6 J.LI correspond to the outlying plots of 
figure 3.3. 
Subsequent assays for the pig brain sample at an initial dilution of 1:10 provided results 
that varied, with a wide range within the same assay (3.1 -4.0 ~g/~1 and 1.46- 2.59 
~g/~1 ) and also across different assays i.e. the values of calculated protein concentration 
were not the same across the range. 
Numerous replicates of pig brain samples using varying volume ranges (0-5 ~I with 
intervals of 1 ~I; 0-20 ~I with intervals of 2 ~I and 0-35 1.1.1 with intervals of 5 J.LI) failed to 
show consistent protein determination results. 
From the Bradford method, it was seen that higher protein concentration corresponded 
with smaller volumes. Another observation was that the protein estimations within the 
assays were not consistent, i.e. the different volumes of sample taken for the carrying out 
of an assay provided different protein concentration Replicates of experiments using pig 
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brain sample and ODC solution could not efficiently estimate the protein content within 
the samples. 
In addition the response of the assay to dilutions of the samples was not proportional to 
the amount of protein in sample, i.e. the absorbance achieved was not proportional to 
dilutions of sample assayed, except for figure 3.4. Using ODC solution of known 
concentration it was determined that the Bradford assay could not effectively determine 
the concentration of prepared samples. It was thus necessary to establish another 
method for the assessment of protein concentration of the prepared samples, in this case 
the Folin Phenol method as discussed below. The result of the determination of protein 
concentration using Folin Phenol assay method could then be compared with the results 
obtained using the BioRad ™. If these results were similar then the irregularities in the 
assessment of the protein concentration would not be dependant on the method but other 
factors. However, a difference in the two results would establish that the BioRad ™ assay, 
as had been suggested, had not accurately assessed the protein concentration 
3.1.2. Folin Phenol Method (Lowry Assay) 
First BSA standard curve was produced. Secondly, an assay was carried out on ODC of 
known concentration and the determined concentration compared to the known 
concentration Lastly, protein determination for pig brain was carried out. 
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Figure 3.5. Standard curve of BSA standards of 1 f.1g/f.11 concentration showing 
absorbance achieved against amount of protein in solution using the Lowry 
method. 
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The figure shows a gQ9Cf linear relationship between amount of protein, i.e. concentration, 
and absorbance achieved. This figure also shows little interference and very smarr 
experimental error. A line was used to assess the graph instead of a smooth curve 
through the points because the points have a good linear relationship. 
Prepared ODC solution of concentration 1.538 f.1g/f.11 was assayed using the Lowry assay 
and a calculation of the protein concentration as assessed by the assay method was 
made (results shown in table 3.4. page 60). A comparison of the calculated protein 
concentration and the known concentration was then made. 
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Table 3.4. Protein estimation for prepared OOC solution assessed by Lowry assay 
method. 
Volume of ODC Amount of protein Dilution and volume 
solution bd) Absorbance at (~g/~1) correction (~g/~1) 
640 nm 
5 0.0285 5.42 5.42 
10 0.0405 7.79 7.79 
The table shows higher protein estimation for the higher volume of sample i.e. 10 ~I than 
the 5 ~1. i.e. protein determination for the two dilutions is not the same. Also, the 
determined protein concentration does not agree with the known concentration of ODC 
solution, which is 1.582 ~g/~1. Note that the volume is directly proportional to amount of 
protein in solution therefore the 10 ~I volume should have twice as much protein as the 5 
~I volume. 
Protein estimation of sample of rat brain. 
A sample of rat brain (homogenisation method II) volumes of 4-201-1-1 of a 1:10 dilution 
assayed as described in section 2. The results of replicate assays were compared to 
assess the difference in absorbance values for smaller volumes compared to larger 
volumes in the BioRad™ assay. Results of these assays are shown below. 
Table 3.5 Protein content as calculated from Lowry assay for 1:10 dilution of rat 
brain sample for volumes 4, 8, 10, and 20 ~1. 
Normal CFA treated (~g/~1) EAE day-13 PI EAE day-21 PI 
{J.tg/~1) (~g/~1) (J.19htl) 
4 J.ll 15.45 17.90 19.60 14.70 
8~ 10.06 11 .89 13.60 10.67 
10 J.ll 9.62 10.0 9.62 9.04 
20 ~I 11 .92 14.04 14.23 12.5 
In table 3.5 a comparison of the amount of protein calculated for rat brain samples using 
four different volumes of sample of a 1 : 10 dilution is shown. The calculated protein 
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concentration for each sample is not the same. The smallest volume shows the highest 
calculated protein concentration (Data shown in appendix X). 
The protein estimation using a range of sample volumes shows two things. Firstly, the 
protein concentration from the absorbance values achieved is not the same for the four 
volumes. Secondly, the difference seen in the calculated protein concentration for the 
four different volumes is too large to be attributed to experimental error. The experiments 
carried out on the samples using the Lowry assay failed to give accurate results of the 
protein content, i.e. the assay did not give the expected protein concentration of prepared 
ODC solution. Also, the assay failed to show a direct relationship between the volume of 
sample taken, which is directly proportional to the amount of protein, and the absorbance 
achieved. 
The Lowry and BioRad™ assay showed different protein concentration values (tables 3.3. 
and 3.5.) for a 1:10 dilution of pig brain with the Lowry assay showing estimated 
concentration frve to six times higher than BioRad TM assay. Thus it was again necessary 
to establish another assay method. The protein assay method chosen was the BCA 
method. 
3.1.3. Bicinchoninic Acid (BCA) Method 
In order to establish the BCA assay in the estimation of protein concentration for the CNS 
samples, and to determine the accuracy of the method, two aspects of the BCA protein 
assay were tested. Firstly, BSA standards were prepared using homogenisation medium 
and water as diluents as per kit instructions. Comparison of these two standard curves 
obtained would show the effect of any interference due to components of the 
homogenising medium in which the samples were prepared. Dilutions of the pure sample, 
1:1 and 1:4, were prepared in both homogenising medium and water, and a range 0.0 _ 
2.0 1.d assayed in triplicate. The absorbance values were taken and the protein 
concentration of each sample volume calculated and corrected for volume and dilution 
factors. 
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Secondly, a sample of prepared ODC solution of known concentration was assayed and 
a comparison of the measured protein concentration with the known concentration made 
i.e. if determined protein concentration equals known concentration of the prepared ODC, 
then the BCA assay method is reasonably accurate. The first part of the assessment of 
the BCA assay method was to produce a BSA standard curve as before (figure 3.6). 
Figure 3.6. Standard curve of protein concentration against absorbance achieved 
for BSA standards (1J.Lg/J.1I) prepared in water using the Bicinchoninic Acid Assay 
method. 
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BCA assay of BSA to produce an equation calculated for a straight line by linear 
regression analysis is shown. The equation may be used for calculations of protein 
1.2 
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concentration Absorbance is seen to be linear and proportional to concentration with little 
deviation from the straight line i.e. little experimental error. (Data shown in Appendix XII) 
Assessment of BCA Assay for protein concentration estimation 
Standard curves of BSA samples prepared in water and homogenising medium were 
plotted and compared (figure 3. 7) following BCA assay kit protocol. Figure 3.8 shows the 
result. 
Figure 3.7. Absorbance achieved for BSA standards of 1f.LgfJ.tl concentration 
prepared in homogenising medium and water as diluents. 
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The standard curves of BSA prepared in both homogenising medium and water produce 
equations of linear regression that are similar suggesting that the use of either diluent has 
little or no effect on the results. Determination of protein concentration in cerebellum 
sample prepared in water and homogenising medium (table 3. 7 and 3.8) was calculated. 
(Data in appendices XIII, X:V and XNI). 
ODC solution of known concentration (1 .0984 J.l.g/J.I.I) was assayed using the BCA method 
at dilutions 1:1, 1:2, and 1:4 with water as diluent. Table 3.6 shows the results. 
Table 3.6 Protein concentration measured by BCA assay estimated for prepared 
ODC solution at different dilutions in water. 
Dilutions Absorbance Amount of protein Corrected for 
(concentration) at 570 nm (f.I.Q/f.l.l) dilution 
1:4 (20%) 0.168 0.288 1.15 
1:2 (33%) 0.246 0.327 1.08 
1:1 (50%) 0.398 0.600 1.20 
Mean ± SEM - - 1.14±0.06 
The average of the concentration for the assay above is 1.14±0.06 ~/IJI. This value 
corresponds closely to the calculated value of the concentration of ODC given above i.e. 
1.0984 IJg/IJI. This accuracy suggests that the assay method is correctly assessing 
protein concentration in the samples assayed i.e. there is lack of any interference (Data is 
given in appendix XIV). 
Dilutions 1 :1 and 1 :4 of sample prepared in both water and homogenising medium were 
assayed using the BCA method and the protein concentration calculated for samples. 
The results are shown in tables 3.7 and 3.8. 
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Table 3.7. Protein concentration of normal cerebellum prepared in homogenising 
medium assayed by BCA method at dilutions of 1:1 and 1:4. 
Dilution Absorbance at Amount of Corrected for 
(Concentration) 570nm protein (J.LghLI dilution (J.LQ/ul) 
1:1 (50%) 0.302 0.4614 0.9228 
1:4 (20%) 0.157 0.2398 1.1990 
Mean ± SEM 
- 1.06±0.27 
-
The protein estimation for the two dilutions is similar i.e. (average ± SEM) 1.06±0.27. 
Data is given in appendix XIV. 
Table 3.8. Protein concentration of normal cerebellum prepared in water assayed 
by BCA method at 1:1 and 1:4 dilutions. 
Dilution Absorbance at Amount of Corrected for 
(Concentration) 570nm protein (J.LQ/J.LI dilution (J.LQ/J.LI) 
1:1 .(50%) 0.379 0.5791 1.1582 
1:4 (20%) 0.149 0.2277 1.1385 
Mean ± SEM - - 1.582±0. 0098 
The determined protein concentration for the two dilutions is similar i.e. (average ± SEM) 
1.1582±0.0098 but slightly higher than that for sample prepared in homogenislng 
medium. Data is given in Appendix 'YN. 
From the results (tables 3.6, 3. 7, and 3.8), it was seen that that BCA assay gave 
consistent and accurate results for different assays of same samples as shown by the 
close agreement between the measured and known concentration ODC solution. 
Although it was determined that the difference in the determination of protein 
concentration using samples made up in either water or homogenising medium is minimal 
(figure 3.7.), water was used as diluent in all subsequent experiments. 
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4.0. RESULTS 
For the western blot analysis, it was important to know the concentration of protein in the 
samples to be assessed. The rat samples were categorised into three experimental 
groups for purposes of replicates. Each group comprised of cerebellum, medulla, and 
cervical spinal cord tissue. Each tissue type was further divided into normal, CFA-treated, 
day-13 PI EAE and day-21 PI EAE tissue. Having standardised the protein assay and 
determined the concentration of samples, it was possible to carry out the estimation of 
protein of the rat samples in preparation for SDS-PAGE and subsequent Western 
blotting. 
4.1. Protein estimation in rat tissue samples for rat brain samples. 
All rat brain homogenate samples were assayed using the BCA assay as described in the 
methods section for SDS-PAGE and following the instructions of the BCA assay kit. Table 
4.1 shows a summary of the protein concentration estimations for analysis set one, two 
and three with dilution factor taken into consideration. 
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Table 4.1 Protein concentration for tissue samples (All values in the table are 
JJQ/JJI.). 
Cerebellum Medulla Cervical Spinal Cord 
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The protein concentration for each rat tissue sample is shown in the table above. The 
protein estimation shown was used for the calculation of the amount of protein in the 
samples prepared for loading. 
The protein concentration of the samples all fall in the same range, a good indication of 
the accuracy of the assay as the weights of the rat tissue (Appendix I) were also in the 
same range. 
The protein of interest in this Western blotting analysis was ODC. It was therefore 
important to find out if the processes of homogenisation, SDS-PAGE and protein transfer 
(from gel to nitrocellulose) would adversely affect ODC. Therefore initial Western blotting 
was carried out with ODC (not shown). ODC solution was prepared for SDS-PAGE 
following the method as the tissue samples. This result was compared with the result of 
a western blot of ODC solution that had not been prepared using the same method as the 
tissue samples and this showed that homogenising medium does not have an effect on 
the ODC solution (figure 3. 7 page 65). 
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4.2. Analysis of rat CNS tissue samples for levels of ornithine decarboxylase using 
the Western blotting technique. 
Determination of protein concentration in the hornogenised rat tissue samples allowed 
accurate loading of samples onto gels for the western blot. Samples volumes containing 
15 ~g of protein from experimental groups one, two, and three were prepared for 50S-
PAGE, loaded onto the gels for each sample of rat tissue i.e., normal, CFA-treated, day-
13 PI EAE and day-21 PI EAE and assessed for levels of ODC as described previously 
(section 2.3 page 56). 
Gel loading was carried out in such a manner as to allow a comparison of the expression 
of ODC in the tissues. Therefore gels were loaded cerebellum-medulla, cerebellum-
cervical spinal cord and medulla-cervical spinal cord. By running two CNS sections on 
one gel it was possible to compare the expression of ODC levels of one tissue relative to 
another. Replicate analyses were carried out and the results are shown I figures 4.1., 4.2. 
and 4.3. Significance of the results was tested using a one-way analysis of variance 
(ANOVA). The photograph of the gel given in the graph is representative of the tissue type 
assessed and not the only raw data from which the graph is plotted. The graphs for 
cerebellum and medulla are for n = 6 (mean ± SEM) while the graph for cervical spinal 
cord is for n = 9 (mean ± SEM). The data is shown in appendix XVII. 
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Figure 4.1 Densitometry result for cerebellum tissue showing the levels of OOC for 
sample loaded onto 12% polyacrylamide gels. 
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Statistical analysis of difference in ODC expression was performed using one-way 
ANOV A The values shown are a relative amount of ODC as determined by absorbance 
levels observed. The amounts represented are relative to the amount in normal tissue. 
There is a significant increase in day-13 EAE PI, P < 0.05 and P < 0.01 ; n = 24. 
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Figure 4.2. Densitometry result for medulla tissue showing level of ODC for sample 
loaded onto a 12% polyacrylamide gel. 
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Statistical analysis of difference in ODC expression was performed using one-way 
ANOV A The values shown are a relative amount of ODC as determined by absorbance 
levels observed. The amounts represented are relative to the amount in normal tissue. 
There is a significant increase in day-13 EAE PI, P < 0.05 and P < 0.01 ; n = 24. 
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Figure 4.3. Densitometry result for cervical spinal cord tissue showing levels of 
ODC for sample loaded onto 12% SDS-PAGE gels. 
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Statistical analysis of difference in ODC expression was perfonned using one-way 
ANOVA. There is no significant increase in day-13 EAE PI , P < 0.05; n = 36. 
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Figures 4.1, 4.2, 4.3, show the analysis of cerebellum, medulla and cervical spinal cord 
samples for ODC levels of expression in nonnal, CFA treated, day-13 EAE PI and day-21 
EAE Pl . The results show that expression of ODC in cerebellum and medulla samples 
was higher at day-13 PI EAE than in any other disease state (figure 4.1 ). However in 
cervical spinal cord, the levels of ODC in the different tissues is not significantly different. 
A large difference is seen in the expression of ODC is seen in cerebellum and medulla 
diseased states between the normal and day-13 EAE PI tissue i.e. the difference in 
expression level from nonnal and CFA-treated tissue with day-13 PI EAE. Cervical spinal 
cord tissue showed the highest levels of ODC all round but showed no differential 
expression. 
In both the cerebellum and medulla tissue there was increased expression at day-13 PI 
EAE followed by a reduction in levels at day-21 PI EAE. 
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5.0. DISCUSSION 
5.1. Homogenisation method 
The initial homogenisation method used on the rat brain was replaced by a second 
method because the initial homogenisation method allowed the collection of only a small 
volume of total sample volume for the tissue samples homogenisecl. The standardisation 
of the protein assay and the Western blotting analysis to follow would both require 
substantial volumes of homogenisecl sample and therefore this initial method was 
inappropriate for use in this study. It was also necessary to optimise use of the rat brain 
tissue available because the tissue was in limited quantity. The second homogenisation 
method used allowed the collection of more total sample volume. 
5.2. Standardisation of protein assay 
Although it was not the aim of this study to evaluate different protein assays, it became 
evident that establishing an assay that could accurately determine the protein 
concentration of the homogenisecl rat brain samples would be an important part of this 
study. Much time and emphasis was spent on establishing a method of protein 
concentration determination that would be both accurate and for which replicate assays 
would give consistent results. With the initial assays used, i.e. BioRad TM and Lowry 
assays, the results obtained were not an accurate determination of the protein 
concentration, as evidenced by inaccurate determination of protein concentration of the 
ODC solution for which the concentration was known. Replicates of experiments carried 
out using the same samples and same protocols also failed to reproduce consistent 
results i.e. repeated protein assays did not give the same results for same samples. 
Initially, to try to rectify the problem of inaccurate determination of protein concentration, 
dilutions of the original samples made in water were assayed in order to minimise the 
effect of potential interfering substances that may be present in the homogenising 
medium used to prepare the samples because diluting with homogenising medium would 
not achieve the desire effect of minimising the concentration of potential interfering 
substances such as dithiothreitol (DTT), SDS, EDTA and Triton X-100. Also diluting the 
73 
sample would bring the concentration into the working range for the standard procedure 
of the BioRad™ assay i.e. 0.2-1.4 fJ.g/fJ.I (Bio-Rad™ protocol, US/EG bulletin 1069; 
BioRact™, 1976). Dilution of the rat brain samples would lessen the noise caused by any 
interfering substances within the sample thus decreasing the value of the SEM. 
When the Lowry assay was used similar problems as those observed with the BioRad™ 
assay were encountered and the method was also cumbersom~ because of the time 
duration and many reagents involved. The range of the Lowry assay for linear results with 
BSA is 1-1 ,500 ,....gtml (Pierce protocols; Lowry, et a/, 1951 ). The Lowry assay also failed 
to accurately determine the protein concentration of the samples as seen from results of 
assay of OOC solution. The Lowry assay may also be affected by interfering substances 
that prevent the accurate determination of protein concentration in a sample. These 
substances include reducing agents, chelating agents, and strong acids and bases. In 
particular interfering substances that should be minimized are EDT A to 1 mM, Tris to 250 
mM, SDS to 1.0%, Triton X-100 to 0.031%, leupeptin to 10 mg/1, and PMSF to 1 mM 
(Pierce instruction books No 0389). 
For both the BioRad ™ and Lowry methods, samples assayed at high dilutions, in 
particular 20% concentration of the original sample, gave the best results i.e. the results 
were in the same range for replicates of the same sample (Figure 3.5 for BioRad ™ assay; 
table 3.5 for Lowry assay). The lower the concentration of the sample the doser to 
expected result and the greater the similarity in protein estimation values across different 
experiments. When the results from the BioRad ™ and Lowry methods were compared, 
there was a large difference in the calculated protein concentration for similar samples. 
These differences were too large to be attributed to experimental error alone and were 
probably brought about by Interfering substances in the homogenising medium. 
The determination of protein concentration of the samples was finally achieved using the 
BCA assay method for which accurate and reproducible values were obtained for both 
the rat brain samples and ODC solution (table 3.6). Experimentation with rat brain sample 
using water and homogenising medium as diluents also showed results within a similar 
range and these results were replicable at different dilutions, 10% and 20% (table 3.8 and 
74 
3.9) i.e. the BCA assay method was more tolerant to potentially interfering substances 
present in samples than the two previously used methods. Also, the working range at 
which the BCA assay works properly is 20-2000 !!gl!!l . This is a wider range than that of 
both the BioRad™ and Lowry assays methods. Of the substances that may interfere with 
the proper working of the BCA assay, the rat brain samples contained NaCI1 M, EDTA 
10 mM, Triton X-100 5%, SDS 1%, Tris 250 mM, and HCJ100 mM (Smith, eta/, 1985; 
BCA assay kit 23225-23227, Pierce). The BCA assay was also much easier to use and 
required Jess time thus making it possible to carry out multiple analyses quite quickly. 
In retrospect, the study would have progressed more efficiently i.e. saving time and 
resources, had a more extensive literature search been carried out on the various protein 
assay methods and their limitations and the equipment and reagents for the various 
assay methods been available such that the assay methods could be assessed 
simultaneously. Also, the standardisation of assays has shown that all initial assays of 
samples of non-pure solutions should be done at dilutions ideally dilutions 1:10, 1:100 
and 1:1000, in water to establish the concentration of the sample, which frts in with the 
range of the protein standard to be used. 
5.3. ODC Expression 
The work discussed In this thesis was carried out to determine the changes, if any, in 
ODC expression in CNS tissue during EAE using the Lewis rat model as described by 
Paul eta/ (2000) and Bolton eta/ (1990). From the evidence available that PA mediate 
BBB disruption and dysfunction it would follow that expression of ODC, the primary and 
rate-limiting enzyme, would also be affected and in this case that ODC expression would 
be increased during the course of the disease. 
It was shown in this study that there are significantly increased levels of expression of 
ODC at day-13 PI EAE for cerebellum and medulla samples with the levels of expression 
in cerebellum at day-13 EAE PI were at least four times as high as the levels observed in 
normal tissue (figures 4.1). In samples of cervical spinal cord, there was no observable 
difference in the expression of ODC between normal and day-13 EAE PI (figures 4.3). 
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Western blotting results of cerebellum sample run with medulla sample and cerebellum 
sample with cervical spinal cord sample on the same gel the distinction between the 
expression of ODC in the four groups (normal, CFA-treated, day-13 PI EAE, day-21 PI 
EAE) was most evident in the cerebellum samples as a comparison of figures 4.1 , 4.2, 
and 4.3 shows. When cervical spinal cord and cerebellum and cervical spinal cord and 
medulla run on the same gel it was observed that the density of ODC bands in cervical 
spinal cord tissue was much higher suggesting that the greatest expression of ODC is 
found in the cervical spinal cord. 
The result seen at day-1 PI EAE is an anticipated result that correlates with evidence 
showing that PA facilitate development and progression of EAE pathology by mediating in 
BBB breakdown (Calder, eta/, 1989; Bolton, 1997; Bolton eta/, 1990). This increase at 
day thirteen and subsequent decrease again at day-21 PI EAE correlate with the course 
of disease. The height of visual clinical symptom development is seen at day-13 EAE PI 
after which, the animal shows decline in symptoms and recovers, usually, around day-21 
EAE Pl. 
The observation of the different levels of ODC In the different CNS sections also ties in 
with the progression of EAE symptoms which are ascending i.e. symptoms are seen to 
occur first at the hind limbs towards the forelimbs and then affecting the cognitive function 
of the brain typified by flaccidity of the tail foiiO\Ned by hind limb weakness, abdominal 
dysfunction, fore limb weakness, and finally cognitive/brain dysfunction (Simmons et a/, 
1982). This progression is also explained by the observation that plaques of 
demyelinated areas are found more commonly in areas of white matter concentration. 
The progression follows the same trend in the CNS by progressing from the cervical 
spinal cord to the medulla and finally to the cerebellum i.e. from the posterior or base of 
the brain to the anterior or fore part of the brain. Ascending progression of symptoms is 
not seen in MS where the symptoms are so varied that the clinical diagnosis of MS 
involves both spatial and temporal pathological evidence and many times is left to the 
"expertise" of clinical neurologists (Poser and Brinar, 2000). It is difficult to correlate 
pathology of MS with clinical features due to their different sizes, frequency and 
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distribution. MS symptoms are usually manifested in a relapsing remitting manner and 
are varied. 
If the level of ODC remains high in the days after day-13, this would suggest a longer 
period of illness because this persistence could be an indication of increased action of 
PA. This increased expression may also support a role of the enzyme in the propagation 
of the disease either facilitating development of symptoms or as a result of another arm of 
the disease process working in a positive feedback process. There seems to be a direct 
relationship between level of ODC expression and presentation of disease symptoms 
especially since at day-21 PI EAE there are reduced levels and remission of symptoms. 
The initiation of EAE involves the breakdown of the BBB (Hawkins et a/, 1991 ; Bolton, 
1997; Rabchevsky et at, 1999; Huber et at, 2001) for which PA have been implicated 
(Koenig et at, 1989; Koenig et at, 1992; Paschen, 1992; Shohami et at, 1992; Baskaya et 
a/, 1997; Bolton, 1997). The accumulation of natural PA is toxic (Urdiales, et a/, 2001) 
and may contribute through various ways to pathology as is suggested for MS and EAE 
(Hawkins et at, 1991; Bolton and Paul, 1997; Paul et at, 2000). 
Significant points along the disease course can be correlated to CDC/polyamine 
expression and initiation probably correlates with initial increased expression of ODC and 
concomitant production of PA leading to the breakdown of the BBB. As the level of ODC 
increases up until day-13 the level of PA also increase and with this increase is an 
increase in clinical symptoms. At this point, the negative feed back regulatory mechanism 
of PA on ODC production may come into play thus leading to decreased ODC production 
and removal of already present ODC through activation of production and action of 
antizyme later on in the course of disease at day-21 . 
This progression of events seems be logical and acceptable however, studies have 
shown that clinical symptoms of EAE in Lewis rats preceded BBB permeability to small 
molecules by one day in the lumbar spinal cord region, while in other regions permeability 
to small molecules coincided with onset of clinical disease (Juhler et at, 1984). This may 
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be an explanation for the results obtained in this study in which there is a higher general 
expression of ODC in cervical spinal cord CNer cerebellum and medulla. If the levels of 
ODC are generally higher even in normal tissue of cervical spinal cord as compared to 
other sections of the brain then this may be a factor determining the early presentation of 
clinical symptoms of EAE prior to BBB breakdown in this section in comparison to other 
sections of the brain where BBB breakdown coincides with the onset of clinical disease 
although other factors may be involved. On the otherhand, results of a study by Juhler et 
a/ (1984) suggest that presentation of clinical symptoms is not necessarily primarily 
dependant on a mechanism driven by polyamine mediated BBB breakdown and also that 
in the spinal cord region, there may be other events that occur that initiate or facilitate 
EAE before the manifestation of breakdown of the BBB and conversely that there is 
activation of the immune response within the CNS before cellular infiltrates ofT -cells and 
macrophages not related to the CDC/polyamine synthetic process. In this case, the 
ODC/PA pathway INOuld serve to further the development of the disease rather than be 
an initiating factor. In another study with guinea pigs, Hawkins eta/ (1991) showed that 
lesions that developed during EAE occurred in the areas of maximal BBB breakdown that 
exhibited diffuse perivascular inflammation. This suggests that although in some 
instances the CDC/polyamine synthetic pathway may not initiate the presentation of 
symptoms it does play a role in the initial stages and progression of the course of the 
disease. 
Paul eta/ (2000) in a study in which 99my"c-RP128 was intravenously administered to 
animals, showed that in other CNS regions, the breakdown of the BBB was an important 
event in the initiation of clinical symptoms of EAE. Day-13 PI, at which increased levels of 
ODC were found in this study (figures 4.1, 4.2, 4.3), corresponds to the time at which 
increased levels of large size substances have been measured on the CNS side of the 
BBB (Paul eta/, 2000) adding support to the proposition the time during the disease 
when levels of ODC are highest is the time when the BBB is most permeable, thus 
suggesting that ODC/PA have a role in BBB dysfunction. Results from Paul eta/ (2000) 
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also showed that large quantities of ~c-RP128 crossed the BBB in CNS tissue of all 
EAE animals compared to CNS tissue of nonnat animals, which is an indication of a 
dysfunctional BBB and that the greatest movement i.e. highest amount of ~c-RP128 
was observed in cervical spinal cord. Similarly, in this thesis, it has been shown that the 
highest levels of ODC detected are in the cervical spinal cord (figure 4.3). Paul eta/ 
(2000) also studied the accumulation of 1251-RSA within the cerebellum, medulla-pons and 
cervical spinal cord at 5, 10, 11, 12, 15,23 and 35-37 days Pl. They showed the earliest 
increase in 251-RSA in cervical spinal cord and therefore for the same duration of time, the 
greatest increase should occur in the cervical spinal cord in comparison to the cerebellum 
and medulla pons. This observation tends support to the finding of greater levels of ODC 
in the cervical spinal cord especially if the ODC/PA pathway is involved in BBB 
dysfunction i.e. the level of ODC starts increasing at an earlier stage and possibly at a 
faster rate and so the accumulation of ODC would be highest in the cervical spinal cord. 
The accumulation of 1251-RSA in cerebellum is slower and sloiNer yet in the medulla and 
suggests a later "opening" of the BBB. 
Using CFA and incomplete Freund's adjuvant, Rabchevsky eta/ (1999) showed that BBB 
breakdown could occur without reactive gliosis if cellular damage and T cell infiltration do 
not occur. This suggests that the mechanism mediating BBB breakdown in itself does not 
lead to the pathological events seen in EAE and that the opening of the BBB must be 
accompanied by the infiltration and activation of reactive T cells to cause pathology. 
Similarly, the opening of the BBB as shown by Paul et a/ (2000) simply suggests a 
relationship between the development of clinical symptoms with penneability of the BBB 
which I link with results from this thesis with increased expression of ODC. The following 
events i.e. cellular infiltration and the inflammatory response are most likely guided by 
different events. 
The vast numbers of studies that have been carried out on the ODC/PA synthetic 
pathway has concentrated on P A Not as many studies have been carried out on the 
difference in levels of expression and localization of ODC in inflammatory disease. PA 
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synthesis and metabolism are associated with various forms of brain injury (Fage eta/, 
1993) such as ischemia and cold injury. Ischemia is an inadequate flow of blood to a 
certain area of the body caused by blockage or constriction of blood vessels supplying it. 
Similar events occur in the pathogenesis of both ischemia and EAE, especially in terms of 
BBB dysfunction and insight into the mechanisms involved in ischemia may provide a 
better understanding of the mechanisms involved in the pathology of EAE and therefore, 
help in the development of therapeutic methods. Cellular changes as a result of ischemia 
in the brain lead to breakdown of the blood-brain barrier, causing malignant cerebral 
oedema that can be seen clinically by a rapid neurological deterioration (Croll and 
Weigand, 2001) and there is a nudear response with increased expression in the 
perinuclear cytoplasm and dendrites of neurons (Paschen, 1992). The pathogenesis of 
ischemia and the subsequent return to normal of blood flow (reperfusion) involves 
cytokine production, astrogliosis, cytoskeletal protein degradation, inflammatory cell influx 
and breakdown of the BBB (Chen eta/, 2001) occurrences that can also be seen in the 
pathogenesis of EAE and MS. PA and NMDA receptors are both thought to play an 
important role in secondary neuronal injury after cerebral ischemia (Dogan et a/, 1997) 
another feature similar to EAE and MS pathology in which calcium ion dependant NMDA 
upregulation of ODC leads to PA production (Bolton, 1997) a process generated by 
activation of the NMDA receptor located at neuronal and cerebrovascular sites (Bolton, 
1997; Bolton and Paul, 1997). Dogan eta/ (1997) showed that for an animal model of 
ischemia, animals given intravenous infusion of ifenprodil showed reduced brain oedema 
and infarct volume as compared to animals that had saline infusion during ischemia 
through the inhibition of PA action although the precise mechanism is unknown. These 
findings are supported by similar studies by Baskaya eta/ (1997) in which it was shown 
that both ischemic injury size and BBB permeability were smaller in the ifenprodil-treated 
group, compared with the saline-treated group. Since ifenprodil is a non-competitive 
inhibitor of PA sites at the NMDA receptor, the use of ifenprodil may, in the case of EAE 
and MS, provide a mechanism for control of the PA mediated breakdown of the BBB. 
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An immunohistochemical study of the cerebellum tissue, medulla tissue and cervical 
spinal cord tissue i.e. CNS sections used in this study, may provide an explanation as to 
why cervical spinal cord shows the highest band density. There is not much information 
on the exact cellular or subcellular location of ODC (Anehus eta/, 1984; Schipper eta/, 
1999) although the highest concentration of ODC in any cell population is always seen in 
the most rapidly proliferating cells (Anehus et a/, 1984; Muller et a/, 1986; Koibuchi et a/, 
1990; McCann eta/, 1992; Fage eta/, 1993). Immunohistochemical studies on rat tissues 
for ODC have shown high staining for ODC in nucleoplasm of mitotic cells, and 
cytoplasmic immunostaining showed ODC in epithelial cells of kidney, prostate and 
adrenal medulla of testosterone-treated rats, and in the glandular epithelium of small 
intestine and pancreas of neonatal and adult rats (Schipper et a/, 1999) all cells with high 
activity. This would suggest that it is possible that before the BBB breaks down there is 
increased cellular activity responsible for the increased expression of ODC and thus 
increased PA expression leading to BBB disruption, the reason for the increased cellular 
activity being varied. 
Studies in models of ischemia by Muller eta/ (1991) showed immunoreactivity of ODC in 
neurons, and even higher reactivity in the perinuclear cytoplasm and dendrites of 
neurons, and in the hippocampus. In the adult human brain ODC reactivity was found in 
the hippocampus and in the spinal cord (Muller eta/, 1999). However, the main cellular 
locus of ODC in both the mature and immature central nervous system is the neuron 
(Dempsey eta/, 1988; Bernstein and Muller, 1998). An immunohistochemical study at the 
BBB might show whether the Increased ODC expression is internal to the CNS or occurs 
in the peripheral vascular system or within the cells of the BBB itself i.e. on the luminal or 
ablumlnal side of the BBB. 
During this present study, it was not possible to carry out an immunoh~tochemical 
comparison of ODC immunoreactivity in the CNS for the cerebellum, medulla pons and 
cervical spinal cord. However, it follows that during PA mediated BBB dysfunction, 
immunoreactivity for ODC ~M>Uid be highest at the brain vasculature especially at areas of 
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leakage of the 888. Regulation of the levels of ODC either through manipulation of the 
production of antizyme or with the use of ODC inhibitors localized to these sites may 
prove to be beneficial in the prevention of 888 breakdown and thus retard or stop 
disease progression. 
Between day-13 PI EAE and day-21 PI EAE there is decrease in ODC levels in 
cerebellum and medulla. Under normal physiological conditions, the levels of ODC are 
regulated by antizyme (AZ), negative feedback regulation due to build up of PA and the 
fact that ODC has a short half-life. AZ. is a natural inhibitor of ODC and works by negative 
regulation of PA but may also degrade ODC (Suzuki eta/, 1994; Mitchell et a/2002). The 
highest levels for AZ genes in the adult rat brain have been detected in the cerebellar 
cortex, hippocampus, hypothalamic paraventricular supraoptic nuclei , locus coeruleus, 
olfactory bulb, piriform cortex and pontine nuclei (Kilpelainen eta/, 2000). AZ. production 
is PA stimulated and seems to function by regulating PA uptake (Coffino, 2001; Scoriconi 
eta/, 2001) leading to the accumulation of spermine (Suzuki eta/, 1994) suggesting that 
AZ. has a higher affinity for the PA transport protein than for ODC enzyme. This implies 
that although AZ. can degrade ODC (Murakami eta/, 2000), the inhibitory function is 
mediated through prevention of PA uptake. In the degradation of ODC, AZ. dissociates 
the ODC dimer and forms an inactive heterodimer of ODC: AZ. and this heterodimer is 
degraded by proteosome 26 S (Zhu eta/, 1999; Murakami eta/, 2000). Under normal 
circumstances, ODC levels are closely regulated and a dysfunction in this regulatory 
mechanism is lethal. Also, since AZ. is the only protein that has been shown to interact 
with ODC, depletion of AZ or dysfunctional synthesis of AZ. may lead to the accumulation 
of ODC and PA levels (Toshlkazu eta/, 1994). The action of AZ provides another 
pathway that may be studied to determine the action of ODC. The dysfunction in AZ. 
production and function may lead to the increased expression of ODC and thus 
accumulation of PA. During the disease itself, decrease in ODC levels may be attributed 
to its regulation by AZ and this may be ascertained by studying the levels of AZ 
production alongside the ODC expression during the EAE disease course. Manipulation 
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of AZ levels may thus provide an avenue for therapeutic regulation of ODC and the 
effects of dysfunctional ODC expression. 
As has been mentioned briefly before, an important drug that used to study the effects of 
ODC inhibition is a-diflouromethylornithine (OFMO). DFMO is accepted as a substrate at 
the active site of ODC and is then converted into a reactive intermediate that forms a 
covalent bond with ODC (McCann and Pegg, 1992). OFMO has been shown to slow the 
growth of tumour cells in vitro and in vivo in animal models (McCann and Pegg, 1992) 
and also shows significant reduction in the volume of oedema, necrosis and brain tissue 
damage, which are indicators of abnormal 888 function (Paschen, 1992). In a time and 
dose dependant treatment of cells, DFMO inhibits growth of cervical precancerous and 
cancerous cells in vitro by inducing apoptosis (Zou eta/, 2002); DFMO inhibits tumours in 
models of skin cancer by inhibiting PA synthesis (Einspahr eta/, 2002). The use of DFMO 
or AZ has been shown to have therapeutic effect in various diseases from various studies 
in both animal models and humans and may provide therapeutic benefit in treatment of 
MS and EAE through its role in regulating ODC. 
5.4. Summary and Conclusions 
This study has shown four important observations. Firstly, that there is a significantly 
increased expression of ODC enzyme in cerebellum and medulla CNS tissue for day-13 
EAE PI tissue as compared to normal, CFA treated tissue and day-21 EAE PI tissue. 
Secondly, that the levels of expression decrease markedly after day-13 EAE PI as the 
disease progresses to day-21 EAE PI when in the Lewis rat, reco.Jery usually occurs. 
Thirdly results of this project show that the CNS section with the highest levels of 
expression of ODC enzyme is the cervical spinal cord. Fourthly, the results show that 
although the cervical spinal cord tissue did show that highest levels of expression of 
ODC, the expression of doeS not follow the expression of the cerebellum and medulla 
tissue i.e. there is no signiflcant difference when normal, CFA treated, day-1 3 EAE PI and 
day-21 EAE PI are compared. These results suggest a role for ODC in EAE pathology. At 
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the height of symptomatic presentation the highest levels of ODC are observed and when 
levels of ODC are reduced towards normal levels, there is remission and recovery. This 
observation supports the suggestion that ODC/PA pathway plays an important role in 
EAE and MS pathology. 
5.5. Recommendations and Future Studies 
In future studies it would be beneficial to establish a profile of the expression of ODC in 
EAE at shorter time intervals such as 24 or 48-hour intervals throughout the duration of 
the disease. Also, the clinical symptoms and their presentation must be closely monitored 
during the disease course such that the relationship between ODC expression and 
clinical symptom presentation can be determined. The point in time at which the level of 
ODC increases above normal i.e. normal being the levels before disease induction, could 
be linked to physiological and physical changes that occur at the same time. 
By using ODC inhibitors to study the effect of regulation of ODC expression on the 
development of these changes that occur as a result of increased ODC above the norm, 
it would also be possible to see the accompanying changes in PA production. 
It would also be important to determine the events that bring down obc levels post day-
13. The mechanisms most suspect in this event, i.e. reduction of ODC levels, are 
negative feedback regulation of the PA and the action of AZ.. It would be necessary to 
determine the profile of the synthesis and metabolism of the PA during the EAE disease 
course in similar time intervals as that taken for ODC. From this result a plot of level of 
expression of ODC and PA against time from inoculation could be plotted and a 
relationship established with reference to presentation of clinical symptoms and recovery 
from disease while at the same time determining the expression of AZ. during the disease 
course. The expression of AZ. would probably be inversely proportional to the expression 
of ODC during disease expression, however, the point at which antizyme expression 
would come into play during the disease may also present a picture of when and how the 
recovery process begins and if indeed AZ. regulation of ODC occurs during EAE. 
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Immunohistochemical localisation of the enzyme would detennine the precise location of 
ODC before and during the disease, again along a time interval of 24 or 48 hours. More 
specifically, detennination of ODC expression at or in close proximity to the 888 from the 
time of inoculation, through the opening of the 888 to the initiation of disease and 
through to the point at which recovery occurs could be detennined by concentrating on 
perivascular tissue. It would therefore be insightful to study the changes in PA expression 
and the physiological and physical changes that occur at 24-hour or 48-hour intervals PI 
at the 888 and on both sides of the 888. Since it has already been shown that PA do 
mediate the opening of the 888, the accompanying physiological and physical changes 
at the 888 could be traced along with the levels of ODC and PA. In this way it may be 
possible to more clearly describe the mechanism by which the PA mediate in the opening 
of the 888. 
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APPENDICES 
Appendix I. Rat Samples weights of rat brain sections. 
Cerebellum 
Rat number Weight (g) Diseased State Date of 
collection 
Q) 7 0.280 Day 13 EAE 14/11/00 c: 
0 6 0.270 Day 21 EAE 14/11/00 
8 0.270 Normal 14/11/00 
6 0.270 CFA treated 14/11/00 
3 0.2869 Normal 14111/00 
~ 8 0.2967 Day 21 EAE 08/02/01 4 0.2361 Day 13 EAE 14/11/00 
4 0.2595 CFA treated 14/11/00 
3 0.250 Day 13 EAE 14/11/00 
~ 1 0.300 Day-21 EAE 08/02/01 
.s::; 7 0.300 Normal 08/02/01 1-
5 0.260 CFA treated 14/11/00 
Medulla 
Rat number Weight (g) Diseased State Date of 
collection 
Q) 7 0.180 Day 13 14/11/00 c: 
0 4 0.170 Day21 08/02/01 
8 0.180 Normal 08/02/01 
6 0.190 CFA treated 14/11/00 
4 0.1696 Day 13 EAE 14/11/00 
~ 8 0.1023 Day21 EAE 08/02/01 3 0.1516 Normal 14/11/00 
4 0.1613 CFA treated 14/11/00 
3 0.190 Day 13 EAE 14/11/00 
~ 1 0.190 Day-21 EAE 14/11/00 
.s::; 7 0.200 Normal 14/11/00 1-
5 0.180 CFA treated 14111/00 
Cerv·cal S · I C d I ;pma or 
Rat number Weight (g) Diseased State Date of 
collection 
Q) 7 0.3669 Day 13 EAE 14/11/00 c: 0.2822 Day21 EAE 14/11/00 0 3 
3 0.2423 Normal 14/11/00 
1 0.2609 CFA treated 14/1 1/00 
1 0.327 Day 13 EAE 14/1 1/00 
~ 2 0.270 Day 21 EAE 08/02/01 9 0.228 Normal 08/02/01 
7 0.229 CFA treated 14/1 1/00 
4 0.310 Day 13 EAE 14/11/00 
~ 8 0.247 Day 21 EAE 08/02/01 
.s::; 8 0.325 Normal 08/02/01 1-
0.269 CFA treated 14/1 1/00 5 
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Appendix II 
Interfering substances (BCA Assay kit, PIERCE ENDOGEN). 
IE 7 
............ 
5 ....... Co..,.... ........ c.~ 
o...rwo-
ACI!S, pH .I 25rMI 
Al'r'ln0tlllll10161e 1.5M ~=.Btt,•a 5~ 1.0% 
Aepnglne 1 .... 
- . pH8.4 20mM 
a;r..Trtt,pHU , ..... 
-(!iOmM),pHillitiO&IIM) .......... 
8-PER" ,__,, (1711248) .......... 
c-...-~ TN. pH 7.Z 10noM 
CIW'S. CIW'$0 5.0% 
Oeoxychallc- 5.0% 
~PX 1.0% 
OI:Cl'lllil.._ 5.1)% 
--(IP..O) ~.()% 
Oclyl !l-lh~ 5.0" 
.....C.boo ........ ll::wtloe<*(0.2M), unoAIIod 
pH t .4 (1211382) 
80S 6.0% 
spen•20 1.Dllo 
~- 100roM Ct£S, pH9.0 100mM 
~(0.811).~(0.1 1:8dlulloo' 
~~~ pH 9.0 (1211!81) 
n11on·~1oo 5.0% 
rrtton•x.114, X.;!05,X~ 1.0% 
,_.-211, r-•-ta, ,_•-ta 5.0% 
~1911'1"~14 1.0% 
~ (0 .8 M), MOPS (0 .1 M~ pH 7.5 1:8-· ~ ..... 
(,_) EOTA 10mM 
~ chlorfdo In TIIS, pH 7.2 o.aooM 
EPPS, pHI.O 100mM 
EGTA -
Sodkml- 200mM 
Ferrtcahbldeln 18S. pH 7.2 10!1lM 
_ .. 
~ lmM ~-.PIIS, pH7.2 IOmM 
GuonldnoHCl 4N 
"""""'"'-
--
HB'ES, pH7.5 10011M 
- . pH7.0 50 111M 
M£ll,pH8.1 IOO,.M 
IEIP.1~NICip.-~!f1._7j111131111) .......... 
CywiHit -
lllllloofyllrtl (DTE) lllllot 
~IOI(DTT) 1..U 
-
tO..W 
MOPS,pH7.2 100..U 
-
-
-CdlooaiaPIIII, Pi 7.411Sl74) 
... -
z .......,..,... .... 0.01llo 
NiollolahbldelnTIIS,pH7.2 10..W -...~ S.OM 
PB8;~(0.1 Ml ~P,I5M), 
... -
~ 0.01llo 
pH7.2(-n) 
-.......-&-
PI'ES,pHB.8 10011111 
-
10'11. 
-~bollr;I!OntiTIIr.leo""NiiCl .......... ~ 1lloN'40,0.1'11.Sll!l,pHI.O --
10llo 
Apoollnln 10 ....... 
SOcllon-.... pHU 200- DMF 10'11. 
--
0~ Oloi80 10% 
---
100- E- 10'11. 
--
1M ~(F-) 10'11. 
Sodkm-, pH 4.8 or pH B.A 200-
SOCiurn .....,... IOOII!M 
Trtcn, pHI.O Z5111M 
r,-.,..,.,... pH 7.8 25 .... 
~~ .. NeCHI!tlo) -
~- 100111M  10'"Ijl\. 
--
10% 
Trio 250..W PllonoiRod -
TIIS; Tria (25 mMl NoCI (0.15 M). pH 7.8 
--(11283781 -
111111 
-ltplmoide 100mM 
T~1 (25 mM), GtyeN (1812 ,.M), pH 8.0 1:3-
(128380) 
a..a.. 40% 
TLCI< 0.1 ........ 
T~• (26 111M). Gl)ocN (1f2 mlol), 80S 
-(0.1"), pH 8.3 (t2&!78) 
lPCK 0.1119\. 
UrN 3M 
Zinc chlcrldt ~ TBS, pH 7.2 10mM _...,._.....,..,PIIS.pH7.2 1 mW 
• Dillllod with dH,O. A biJd< iadicllciU.t the ..-lalla illllOiq>AIIble with 1he -.y. 
TelephoM: ... -PIERCE ~.w723) or.,~ .. 7 • I' a: 115-41U-7S1S cw Ml-842.-oT 
_....,..___, • ~leiYtoe: ~ • Technlcel .-.....__: ...,..._...-
5 
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Interfering substances. (Smith, P. K., eta/, 1985, page 79.) 
PRO'TEIN ASSAY USING BICINCHONli\'IC AOO 79 
TABLE I 
EI'PICT o, SaucnD Pon:m.u nrrrofl!JUHO CONI'Olli'ID5 
IleA -y ( ... IIA boR4) Lowry- (1'1 BSA fCMIAI) 
Sompk: (SO Pa BSA) in lhc w-biul< rntufere.oce blank Wat<tblank lnl<rl....,.. blank 
ro11owtns: CClmC1Cd CGmCI«S -..c:ted c:cmciOd 
so,..asAin,....,!refe<onet) 50.00 so.oo 
0.1 N lfO :l0.10 S0.80 400 4J.IO 
0.1 N NoOH 49.00 4'-40 )0,60 30.60 
o.r. sodium azide 51.10 S0.90 -49.20 49.00 
0.0211 oodium uidt 51.10 51.00 49.SO 49.60 
1.0 M IOdiuaa chloride suo 51.10 30.20 50.10 
• 100 l1llo< EOTA (4 NaJ No color lli.SO 5.10 
•so mN EDTA (4 Na) 28.00 29.40 ,6.10 6.80 
-10 mN £DTA (4 No) 48.80 4~. 10 )3.60 12.70 
1o:lOmNEDTA(4No~pH 
11.25 31.50 )2.80 72.)0 5.00 
4.0 N _.;din< HCI 48.JO 46.90 ~ 
J.o ...... 51 .30 50.10 53.20 '45.00 
1.011 Tricoa X· IOO 50.20 49.80 Ptocipitated 
"1 .01 50S (Iaury!') <1!1.:10 41.90 .........-
t.OIIIlriJ3S ,. .00 S0,90 l'n<illilllled 
1.011 Lum.J 50.10 :10.10 l'noci!Jillted 
I.O.Chopo 49.90 .~.50 Pnlcicllllllod 
! .Ole.- 51.10 St.OO ~
1.011 octYIIJiucOiid< 50.90 :tOJJO f'redP.Ialld 
40.0\l.s..,... 55.40 41.70 4.90 28.90 
10.0\l.s..,_ :12.50 50.50 42.90 41.10 
1.0'1. ... - suo Sl.lO 41.40 41.10 
100--- 245.00 S7.10 61.10 61.70 
so ........... 144.00 47.70 62.10 SUl 
10_......., 70.00 ~. 10 52.60 51.20 
0.2 M JOrbi1ol 42.90 31.80 63.10 31.00 
0.2 .. JOrbilol, pH 11.2.! 40.70 )6.20 61.60 26.60 
1.0 M IIYtine No color 7.:10 7,7() 
1.0 M&IJc:l•. pH II. 50.70 41.90 32.50 27.90 
O.SNTrio )6.20 )2.90 10.20 8.11!0 
O.l.!MTrio 46.60 44.00 27.90 28.10 
.O.IwTrto 50.10 49.60 38.90 11.90 
0.25 wTrlo,pH 11.25 52.00 50.:10 40.10 40.11!0 
20.()1.1 ammonium aulfa~ HO 1.20 P'rcipiaoled 
IOJlll, &IDmoniom _,_ 16.00 12.00 l'ledpiaoood 
l.o!lllln ................. 44.90 42.00 1J.20 21 .40 
IO.O!hmnmiom """"'- pH 11 . 41.10 45.20 32.60 .ll.IO 
2.0 M oodium - pH '-S 3$.50 ;~< .SO 5.40 3.30 
0.2 ., .odium -..e, pH H 50.80 SOAO 47. l0 47.60 
1.0 .. """"'" .,.,...,__ 37.10 )6.20 7.)0 S.30 
O.louodium ~ 50.10 l0.40 46.60 ~.60 
0.1 .1o1 Cilium bb- oii!J.SO 49.70 Pr<o:ipi-
italions of the Lowry proccdun:. AA shown in coloRd chromopbQn: with an lblotblnce 
As. 1, bicinchoninic llcid can fbrm a 2: I com- mulmum at 562 nm (3). We have fouad that 
plc:x with Cu1• , re~~~ltin' in a stable, biala!Y it ia po~m'ble to ID8k.c usc of tbia.n:action to 
.... : • ··· 
..... :-!.;....:: ·~ • :. '\ ;..., <l.' 
The table shows substances that interfere with the proper assessment of protein 
concentration when using the BioRad™, Lowry and BCA assay methods. 
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Appendix for Ill 
Whole gel 
The gel below shows cervical spinal cord and cerebellum tissue run together. The lanes 
were loaded (from right to left) using prepared ODC solution for positive control , 
cerebellum, i.e. nonnal, CFA-treated, day-13 PI EAE and day-21 PI EAE, molecular 
weight marker, and cervical spinal cord, i.e. nonnal, CFA-treated, day-13 PI EAE and 
day-21 PI EAE. 
~ ot 
n> ~ ~ f ..,..;"' ""' \~ t-l< _/ 4., f' 
"0 "\ cJ 1" "' v (,I .,. t' 
. '·;... so~'b~ 
.. . ' 
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Appendix IV. Figure 3.1 
The range of BSA used was 0.0, 0.125, 0.250, 0.500, 0.750, 1.000, 1.500, and 2.000 !JI 
from a 11Jgi1JI solution. Tables show the achieved absorbance for samples of BSA using 
the BioRad ™ assay method. 
Table for BSA standards with three replicates given as runs one, two and three. (Volume 
and concentration are equivalent since concentration is 1 !J.g/!J.I.) 
Absorbance Achieved at 570 nm 
Volume of Run Run Run Total Mean Corrected 
sample (JJI) one two three for blank 
0.000 0.003 0.005 0.002 0.010 0.003 0.000 
0.125 0.047 0.052 0.051 0.150 0.050 0.047 
0.250 0.097 0.098 0.105 0.300 0.100 0.097 
0.500 0.270 0.410 0.370 1.050 0.350 0.347 
0.750 0.550 0.570 0.550 1.670 0.557 0.554 
1.000 0.680 0.800 0.620 2.100 0.700 0.697 
1.500 1.000 0.800 0.900 2.700 0.900 0.897 
2.000 1.430 1.470 1.300 4.200 1.400 1.397 
Appendix V. Figure 3.2. 
BSA standards 
Volume of BSA (JJI) Run one Run two Run three Mean Corrected value 
0.0 0.299 0.288 0.290 0.292 0.000 
3.0 0.483 0.482 0.481 0.482 0.190 
5.0 0.843 0.863 0.897 0.868 0.576 
6.0 0.929 0.950 0.948 0.942 0.650 
7.0 0.916 0.939 0.912 0.922 0.630 
8.0 1.076 1.093 1.075 1.081 0.789 
10.0 1.113 1.106 1.124 1.114 0.822 
15.0 1.261 1.217 1.261 1.246 0.954 
Prepared ODC solution 
Run one Run two Run three Mean Corrected value 
Volume of ODC (JJI) 
0.0 0.290 0.287 0.295 0.291 0.000 
3.0 1.005 1.142 1.212 1.120 0.829 
5.0 1.340 1.304 1.376 1.340 1.049 
6.0 1.446 1.476 1.523 1.482 1.191 
7.0 1.504 1.563 1.564 1.544 1.253 
8.0 1.587 1.558 1.672 1.606 1.315 
10.0 1.540 1.649 1.694 1.628 1.337 
15.0 1.648 1.690 1.781 1.706 1.415 
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Appendix VI. Table 3.2. 
Retrial with spot volumes of ODC 
BSA standards 
Absorbance achieved at 570 nm 
Volume of BSA (pi) Run one Run two Run three Mean Corrected value 
5.0 1.055 0.870 0.360 0.762 0.436 
10.0 1.315 1.274 1.304 1.298 0.999 
15.0 1.425 1.420 1.669 1.505 1.206 
20.0 1.507 1.527 1.559 1.531 1.232 
25.0 1.597 1.607 1.636 1.613 1.314 
Prepared ODC solution 
Absorbance achieved at 570 nm 
Volume of ODC (pi) Run one Run two Run three Mean Corrected value 
5.0 1.507 1.352 1.451 1.437 1.145 
10.0 1.721 1.597 1.712 1.677 1.385 
15.0 1.723 1.708 1.752 1.728 1.436 
Appendix Vll1:10 Dilution of pig brain sample- figure 3.3. 
BSA standards 
Absorbance achieved at 570 nm 
Volume of BSA (1pg/pl) Run one Run two Mean Corrected value 
0.0 0.340 - 0.000 
1.0 0.431 - 0.091 
2.0 0.554 - 0.214 
3.0 1.029 - 0.689 
4.0 0.812 - 0.472 
5.0 0.908 - 0.568 
6.0 1.205 - 0.865 
7.0 1.169 - 0.829 
Pig brain sample 
Absorbance achieved at 570 nm 
Sample volume (1..11) Run one Run two Run three Mean Corrected value 
0.0 0.322 0.322 0.332 0.325 0.000 
1.0 0.353 0.385 0.371 0.370 0.045 
2.0 0.426 0.343 0.491 0.420 0.095 
3.0 0.417 0.474 0.462 0.451 0.126 
4.0 0.518 0.508 0.476 0.501 0.176 
5.0 0.533 0.576 0.574 0.561 0.236 
6.0 0.640 0.569 0.520 0.576 0.251 
7.0 0.626 0.629 0.536 0.597 0.272 
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Appendix Vlll1:1000 Dilution of pig brain sample- figure 3.4. 
BSA standards 
Absorbance achieved at 570 nm 
Volume of BSA (11JQ/1JI) Run one Run two Mean Corrected value 
0.0 0.340 - 0.000 
1.0 0.431 - 0.091 
2.0 0.554 - 0.214 
3.0 1.029 - 0.689 
4.0 0.812 - 0.472 
5.0 0.908 - 0.568 
6.0 1.205 - 0.865 
7.0 1.169 - 0.829 
Pig brain sample 
Absorbance achieved at 570 nm 
Sample volume (J.LI) Run one 
0.0 0.328 
1.0 0.336 
2.0 0.333 
3.0 0.342 
4.0 0.345 
5.0 0.352 
6.0 0.343 
7.0 0.351 
Appendix IX. Figure 3.5 
BSA standards 
Volume of sample Run 
ful) one 
0 0.322 
1 0.353 
2 0.426 
3 0.417 
4 0.518 
5 0.533 
6 0.640 
7 0.626 
Amount of 0 1 
protein 
BSA (J1g) 
Absorbance 0.340 0.451 
achieved (0.000) (0.091) 
At 570 nm 
Run two Mean Corrected value 
0.323 0.326 0.000 
0.326 0.331 0.005 
0.339 0.336 0.010 
0.343 0.343 0.017 
0.344 0.345 0.019 
0.337 0.345 0.019 
0.342 0.343 0.017 
0.360 0.356 0.030 
Absorbance achieved at 570 nm 
Run Run Total Mean 
two three 
0.322 0.332 0.976 0.325 
0.385 0.371 1.109 0.370 
0.343 0.491 1.260 0.420 
0.474 0.462 1.353 0.451 
0.508 0.476 1.502 0.501 
0.576 0.574 1.683 0.561 
0.569 0.520 1.792 0.576 
0.629 0.536 1.791 0.597 
2 3 4 5 
0.554 1.029 0.812 0.908 
(0.214) (0.689) (0.472) (0.568) 
Values '" brackets are absorbance values corrected for blank. 
Corrected for 
blank 
0.000 
0.044 
0.095 
0.126 
0.175 
0.236 
0.251 
0.272 
6 7 
1.205 1.169 
(0.865) (0.829) 
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Appendix X. Figure 3.6 
Absorbance achieved at 570 nm 
Volume of sample htl) Run one Run two Run three Total Mean 
0 0.000 0.000 0.000 0.000 0.000 
5 0.040 0.036 0.035 0.114 0.038 
10 0.082 0.063 0.073 0.218 0.072 
15 0.102 0.165 0.134 0.401 0.134 
Table 3.5 Medulla (4 and 8 J.LI) 
Volume of BSA h.ll) Run one Run two Mean Corrected value 
5.0 0.052 0.062 0.057 N/A 
10.0 0.080 0.078 0.079 N/A 
20.0 0.100 0.101 0.101 N/A 
30.0 0.143 1.135 0.139 N/A 
Nonnal 
Volume of sample h.ll) Run one Run two Mean Corrected value 
4 0.030 0.330 0.315 N/A 
8 0.044 0.043 0.044 N/A 
CFA-treated 
Volume of sample (tJI) Run one Run two Mean Corrected value 
4 0.035 0.038 0.037 N/A 
8 0.051 0.046 0.049 N/A 
D 13 P ay- IEAE 
Volume of sample (t.al) Run one Run two Mean Corrected value 
4 0.042 0.038 0.040 N/A 
8 0.056 0.055 0.056 N/A 
D 21 PIE ay- AE 
Volume of sample (t.al) Run one Run two Mean Corrected value 
4 0.029 0.031 0.030 N/A 
8 0.043 0.044 0.435 N/A 
Figure 3.6 Medulla (10 and 20 J.LI) 
Volume of BSA (t.al) Run one Run two Mean Corrected value 
0.0 0.036 0.035 0.036 N/A 
5.0 0.054 0.052 0.053 N/A 
10.0 0.084 0.087 0.086 N/A . 
15.0 0.098 - 0.098 N/A 
25.0 0.126 0.127 0.127 N/A 
35.0 0.160 0.166 0.163 N/A 
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Nonnal tissue 
Volume of sample (l.al) Run one Run two Mean Corrected value 
10 0.052 0.047 0.050 NIA 
20 0.063 0.061 0.062 N/A 
CF A-treated 
Volume of sample (JJI) Run one Run two Mean Corrected value 
10 0.051 0.053 0.052 N/A 
20 0.070 0.076 0.073 N/A 
D 1 P E E ay- 3 I A 
Volume of sample (JJI) Run one Run two Mean Corrected value 
10 0.052 0.047 0.050 N/A 
20 0.077 0.072 0.075 N/A 
Day-21 PI EAE 
Volume of sample (1.11) Run one Run two Mean Corrected value 
10 0.048 0.046 0.047 N/A 
20 0.067 0.062 0.065 N/A 
ODC 
Volume of sample (~I) Run one Run two Mean Corrected value 
10 0.027 0.030 0.029 NIA 
20 0.039 0.042 0.041 NIA 
Appendix XII. Figure 3.6 
Absorbance achieved at 590 nm 
Concentration Run one Run two Run three Mean Corrected 
ofBSA value 
0.000 -0.018 -0.017 -0.037 -0.024 0.0000 
0.200 0.223 0.188 0.173 0.195 0.1710 
0.500 0.549 0.476 0.524 0.516 0.4896 
1.000 0.854 0.852 0.915 0.874 0.8497 
Appendix XIII. Figure 3.8 
Comparison of absorbance achieved when sample is diluted in water and homogenising 
medium. 
Buffer as diluent 
Absorbance achieved at 570 nm 
Vol. of BSA (Jd) Abs. 1 Abs.2 Abs.3 Mean Corrected value 
0.000 -0.021 -0.019 -0.016 -0.019 
0.025 -0.013 -0.012 -0.010 -0.012 
0.125 -0.002 0.022 0.009 0.010 
0.250 0.041 0.055 0.077 0.058 
0.500 0.172 0.205 0.179 0.185 
·-0.750 0.330 0.342 0.345 0.339 
1.000 0.597 0.581 0.585 0.588 
1.500 1.027 0.991 0.969 0.996 
2.000 1.408 1.469 1.450 1.442 
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Water as diluent 
Absorbance achieved at 570nm 
Vol. of BSA (1.11) Abs.1 Abs.2 Abs. 3 Mean Corrected value 
0.000 0.010 0.006 0.006 0.007 
0.025 0.022 0.024 0.024 0.023 
0.125 0.107 0.117 0.119 0.114 
0.250 - - - -
0.500 0.346 0.347 0.344 0.346 
0.750 0.498 0.535 0.519 0.517 
1.000 0.690 0.662 0.669 0.674 
1.500 0.971 0.937 0.953 0.954 
2.000 1.425 1.298 1.308 1.344 
Appendix XIV 
Concentration of prepared ODC solution 
0.00404 g of ODC powder was dissolved in 1.160 ml of analogue water. 
1 mg of solid has 0.41 units i.e. 0.001 g has 0.00041 units. 
103 x 0.00404 g has (0.041/0.00404) units. There are 1.66 x 103 units in solution. But 1 
unit contains 1/1.3 mg of protein. 1/1.3 x 1.66 x 103 mg of protein= 1.27 mg of protein in 
solution .The concentration of the prepared ODC solution is 1.2711 .160 (mg/ml) 
The concentration of the prepared ODC solution is 1.098 mg/ml 
Figure 3.10 
BSA standards 
Absorbance achieved at 570 nm 
Volume of BSA (1.11) Run one Run two Run three 
0.025 0.025 -0.004 0.000 
0.125 0.231 0.094 0.103 
0.250 0.174 0.194 0.187 
0.500 0.332 0.376 0.345 
0.750 0.488 0.477 0.491 
1.000 0.657 0.659 0.695 
1.500 1.012 1.034 0.927 
2.000 1.333 1.295 1.139 
Prepared ODC solution 
ODC Run one Run two Run three Mean 
1 :3 dilution 0.171 0.178 0.186 0.178 
1 :2 dilution 0.251 0.257 0.259 0.256 
1:1 dilution 0.409 0.407 - 0.408 
Mean Corrected value 
0.007 0.000 
0.099 0.092 
0.185 0.178 
0.351 0.344 
0.485 0.478 
0.670 0.663 
0.991 0.984 
1.256 1.249 
Corrected value 
0.168~ 
0.246 
0.398 
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Appendix XV. Table 3.7. 
Normal cerebellum in homogenising medium dilutions 1:1 and 1 :4 
Dilution Abs.1 Abs. 2 Abs.3 Mean Corrected value 
1:1 0.283 0.246 0.321 0.283 0.302 
1:4 0.160 0.133 0.121 0.138 0.157 
Appendix XVI. Table 3.8 
Normal cerebellum in water dilutions 1:1 and 1 :4 
Dilution Abs.1 Abs.2 Abs. 3 Mean Corrected value 
1:1 0.412 0.359 - 0.386 0.379 
1:4 0.173 0.156 0.138 0.156 0.149 
Appendix XVII. ANOVA for the rat tissue samples. 
The F value is the ratio of the difference between groups compared to the difference 
among/within groups. F calculated i.e. mean of squares between groups/mean of squares 
within groups. F = MSb(/MSwg ; the degrees of freedom Fx.y with x = degrees of freedom 
for the groups and y = degree of freedom for total number of samples. 
MSbg = SStotal - SSwg ; SSwg = SSx + SSy + SSz + SSa 
:. MSbg = SStota~ - (SSx + Ssy + SSz + SSa.) 
dfbg is number of groups - 1; dfwg is total number of samples - number of groups 
CEREBELLUM 
Normal CF A-treated day-13 PI EAE day-21 PI EAE 
Rep.1 72.58 116.25 80.49 48.45 
Rep. 2 100.00 48.47 622.22 57.30 
Rep. 3 100.00 32.46 256.18 60.57 
Rep.4 17.60 41 .75 106.79 97.25 
Rep. 5 39.96 23.77 102.57 47.23 
Rep. 6 99.59 86.01 359.81 293.77 
Mean 71 .62 58.12 254.68 100.76 
ss 6314.61 6356.41 221491 .28 46370.98 
SS total 453230.40 MSwg- 14026.66 
SSwg 280533.28 df = 20 MSbg = 57565.71 
ss bg 172697.12 df = 3 F = 4.104 
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MEDULLA 
Normal CF A-treated day-13 PI EAE day-21 PI EAE 
Rep. 1 15.24 7.93 42.43 100.00 
Rep. 2 48.77 10.83 114.10 91 .44 
Rep. 3 40.95 46.25 83.65 64.59 
Rep. 4 29.98 22.64 207.66 69.84 
Rep. 5 45.42 63.50 50.64 100.00 
Rep. 6 95.34 94.32 165.98 128.26 
Mean 45.95 40.91 110.74 92.36 
ss 3670.75 5717.73 21468.37 2684.72 
SS total 58458.06 MSwg = 1677.08 
SSwg 33541 .57 df = 20 MSbg = 8305.50 
SSbg 24916.49 df = 3 F = 4.95 
CERVICAL SPINAL CORD 
Normal CFA-treated day-13 PI EAE day-21 PI EAE 
Rep.1 230.88 251.08 273.27 282.90 
Rep. 2 114.89 114.92 96.68 92.95 
Rep. 3 99.96 265.82 237.11 278.71 
Rep. 4 96.12 81 .35 84.11 86.34 
Rep. 5 98.68 21.52 298.86 195.78 
Rep. 6 178.72 198.20 64.62 136.07 
Rep. 7 84.79 47.18 68.64 71 .37 
Rep. 8 771 .22 971 .30 758.63 770.16 
Rep. 9 99.96 97.95 82.32 99.97 
Mean 197.25 227.70 218.25 223.81 
ss 389220.33 681881 .345 399126.5149 388084.5886 
SS total 1863284.01 MSwg = 58072.27 
SSwg 1858312.78 df = 32 MSbg = 1657.08 
ss bg 4971 .23 df = 3 F = 0.03 
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